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ABSTRACT 
Background: Respiratory infections are a well-established child morbidity 
and mortality cause, which are estimated to cause 75% of all acute illness 
and are the leading cause of hospitalization for infants and young children 
worldwide. There are no methods of treatment or prevention through 
vaccination, except for specific agents (seasonal flu and H1N1) and in 
specific children with risk factors. However, the majority of respiratory 
infections occur in apparently healthy children without identifiable medical 
history, in which also the susceptibility, clinical course and prognosis vary 
widely even being affected by the same virus. Within this spectrum, 
respiratory syncytial virus (RSV) specifically is one of the paradigms of 
pediatric respiratory infection, frequency, morbidity and the absence of 
demonstrably effective preventive or therapeutic measures. While the clinical 
Abstract	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features of ARIs are easily recognized, the etiological agent responsible for 
disease is often not detected, as typically it is used direct 
immunofluorescence to detect RSV, influenza virus, parainfluenza virus and 
adenovirus. In this regard, the etiology of most lower respiratory tract 
infection is thought to be viral, but a virus is identified in approximately 40% 
of cases with this approach. Since the introduction of molecular diagnostic 
techniques, the identification of pathogens that escape from conventional 
modalities has increased. These molecular techniques frequently reveal the 
presence of more than one microorganism in the samples. The importance of 
these co-infections in the pathogenesis, severity or course of these 
respiratory infections is not well established. In the other hand, bacteremia 
risk is considered low in children with acute bronchiolitis and fever. However 
the concrete rates of occult bacteremia in infants with respiratory syncytial 
virus infection is not well established. 
Objectives: The main aims of this study were: 1) to assess using molecular 
diagnosis the epidemiology of viral co-infection in hospitalized children with 
ARI and to evaluate its eventual influence in the clinical manifestations and 
disease course; 2) to determine the actual rate and predictive factors of 
bacteraemia assessed by conventional cultures and molecular techniques in 
children admitted to hospital due to confirmed RVS acute respiratory illness. 
Methods: A prospective observational multicenter study was designed using 
the GENDRES research network (www.gendres.org). The GENDRES 
network was created with research purposes in 2010 for the study of the 
influence of the genetics and vitamin D in respiratory infections, leading from 
Genetic, Vaccines, Infections and Pediatrics group (GENVIP). It includes 
Abstract	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thirteen Spanish tertiary hospitals and more than fifty multidisciplinary 
collaborators. An independent cohort was collected in parallel in the UK for 
comparison purposes. Children admitted to any of the network’s hospitals 
with acute respiratory infection between 2011-2013 were eligible for the 
study. On the top of the conventional diagnostic work-up performed in the 
referring hospital, a real time nested polymerase chain reaction (PCR) 
approach designed to detect Influenza (A and B), metapneumovirus, RSV, 
parainfluenza (1-4), rhinovirus, adenovirus (A-F), bocavirus and 
coronaviruses (NL63, 229E, OC43) was applied to all recruited patients. 
Additionally, in children admitted to hospital because of an acute respiratory 
infection caused by RSV, bacterial presence in blood was assessed using 
PCR for Meningococcus, Streptococcus pneumoniae, Haemophilus 
influenzae, Streptococcus pyogenes, Klebsiella pneumoniae, Pseudomonas 
aeruginosa, Escherichia coli, Staphylococcus aureus in addition to 
conventional cultures. 
Results: A total of 301 subjects were recruited, 204 in GENDRES and 97 in 
the UK with a median age of 6.4 months (first quartile: 2.2, third quartile: 
17.0) in the GENDRES cohort and 20.0 months (first quartile: 7.0, third 
quartile: 48.7) in the UK cohort. In both cohorts, RSV was the most frequent 
pathogen (52.9% and 36.1% samples, respectively). Co-infection with 
multiple viruses was found in 92 samples (45.1%), and 29 samples (29.9%) 
respectively; this was most frequent in the 12-48 months age group. The 
most frequently observed co-infection pattern was RSV-Rhinovirus (23 
patients, 11.3%, GENDRES cohort) and RSV-bocavirus/bocavirus-influenza 
(5 patients, 5.2%, UK cohort).  
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The pattern of co-infection did not correlate with any markers of severity. 
However, bacterial superinfection was associated with increased severity 
(OR: 4.356; P-value = 0.005), PICU admission (OR: 3.342; P-value = 0.006), 
higher clinical score (1.988; P-value = 0.002) respiratory support requirement 
(OR: 7.484; P-value < 0.001) and longer hospital length of stay (OR: 1.468; 
P-value<0.001). In addition, pneumococcal vaccination was found to be a 
protective factor in terms of degree of respiratory distress (OR: 2.917; P-
value = 0.035), PICU admission (OR: 0.301; P-value=0.011), lower clinical 
score (-1.499; P-value = 0.021) respiratory support requirement (OR: 0.324; 
P-value = 0.016) and oxygen necessity (OR: 0.328; P-value = 0.001). All 
these findings were replicated in the UK cohort. 
A total of 66 previous healthy children with a positive RSV respiratory illness 
were included for bacterial detection in blood. In 10.6 % patients bacterial 
presence was detected in the blood, predominantly H. influenzae (n = 4); S. 
pneumoniae (n = 2). In those patients with bacteremia there was a previous 
suspicion of bacterial superinfection in 6 out of 7 patients (85.7%). There 
were also significant differences in terms of severity between children with 
positive or negative bacterial PCR: PICU admission (100 % vs. 50 %, P-
value = 0.015); respiratory support necessity (100 % vs. 18.6 %, P-value < 
0.001); Wood-Downes score (mean = 4.8 vs. 8.7 points; P-value < 0.001); 
the GENVIP scale (mean = 10.1 vs. 17.0 P-value <0.001); and longer length 
of hospitalization (mean = 12.1 vs 7.5 days; P-value = 0.007). 
Conclusion: The presence of more than one virus in children admitted to 
hospital with LT-ARI ranged from one third to two thirds of these patients, 
depending on the age, and being particularly frequent in the second year of 
Abstract	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age, but the clinical significance of this finding remains unclear. The 
presence of more than one virus in hospitalized children with ARI is very 
frequent but it does not seem to have a major clinical impact in terms of 
severity. However bacterial superinfection increases the severity of the 
disease course. On the contrary, pneumococcal vaccination plays a 
protective role. With regards to bacteremia in infants hospitalized with RSV 
respiratory infection, it is not frequently found, even in the presence of fever; 
however, the possibility of bacteremia has to be considered in the most 
severe respiratory diseases. 

	  
RESUMEN 
Introducción: Las infecciones respiratorias constituyen una causa bien 
establecida de la morbilidad y mortalidad infantil, las cuales se estima que 
causan el 75% de las enfermedades agudas y son la causa principal de 
hospitalizaciones en lactantes y niños a nivel mundial. No hay formas de 
tratamiento y prevención a través de la vacunación, salvo para agentes 
específicos (gripe estacional y H1N1) y en individuos concretos con factores 
de riesgo. Sin embargo, la gran mayoría de las infecciones respiratorias 
ocurren en niños aparentemente sanos y sin antecedentes patológicos 
identificables, en los que además la susceptibilidad, el curso clínico y el 
pronóstico son muy variables aun estando afectados por el mismo virus. 
Dentro de este espectro, la infección por virus respiratorio sincitial (VRS) 
constituye específicamente uno de los paradigmas de la infección 
Abstract	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respiratoria pediátrica, por su frecuencia, morbimortalidad y la ausencia de 
medidas preventivas o terapéuticas demostradamente eficaces. Mientras 
que las características clínicas de las IRAs son fácilmente reconocidas, el 
agente etiológico responsable de la enfermedad es a menudo no detectado, 
ya que habitualmente se usa la inmunofluorescencia como método de 
detección para VRS, virus influenza, parainfluenza y adenovirus. En este 
sentido, la etiología de la mayoría de las infecciones respiratorias se cree 
que son virales, pero con este enfoque, solo se identifica el virus en 
aproximadamente un 40% de los casos. Desde la introducción de las 
técnicas de diagnóstico molecular, la identificación de los patógenos que se 
escapan de las modalidades convencionales han aumentado. Estas técnicas 
moleculares con frecuencia revelan la presencia de más de un 
microorganismo en las muestras. La  importancia de estas co-infecciones en 
la patogénesis, la gravedad o el curso de estas infecciones respiratorias no 
está bien establecida. Por otro lado, el riesgo de bacteremia en niños con 
infección respiratoria viral y fiebre se considera tradicionalmente baja. Sin 
embargo, la tasa concreta de bacteremia oculta en lactantes con infecciones 
por VRS no está bien establecida. 
Objetivos: Los principales objetivos de nuestro trabajo fueron: 1) analizar 
utilizando técnicas de diagnóstico molecular la epidemiología de las co-
infecciones virales en niños hospitalizados con IRA y evaluar su eventual 
influencia en las manifestaciones clínicas y curso de la enfermedad y 2) 
determinar la tasa actual y los factores predictivos de bacteremia evaluada 
por cultivos convencionales y por técnicas moleculares en niños ingresados 
en el hospital a causa de una infección respiratoria aguda por VRS.  
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Métodos: Se diseñó un estudio multicéntrico, prospectivo observacional 
usando la red GENDRES (www.gendres.org). La red clínica GENDRES fue 
creada en el año 2010 con fines investigadores para el estudio de la 
influencia de la genética y la vitamina D en las infecciones respiratorias, 
coordinado desde el grupo de Genética, Vacunas, Infecciones y Pediatría 
(GENVIP). Está formada por trece centros hospitalarios distribuidos por toda 
la península y más de cincuenta investigadores colaboradores 
multidisciplinares. Además, los resultados se compararán con una cohorte 
de réplica de Reino Unido. Los niños ingresados por infecciones agudas 
respiratorias en cualquiera de los hospitales de ambas redes entre los años 
2011-2013 eran elegibles para el estudio. Conjuntamente al estudio 
diagnóstico con técnicas convencionales aplicado en el hospital de 
referencia, se realizó una reacción en cadena de la polimerasa (PCR) 
anidada y a tiempo real para detectar el virus influenza (A and B), 
metapneumovirus, VRS, parainfluenza (1-4), rinovirus, adenovirus (A-F), 
bocavirus y coronavirus (NL63, 229E, OC43) a todos los pacientes 
reclutados para el estudio. 
Adicionalmente, en niños que fueran ingresados en el hospital debido a una 
IRA por VRS, se evaluó la presencia bacteriana en sangre para los 
organismos Meningococcus, Streptococcus pneumoniae, Haemophilus 
influenzae, Streptococcus pyogenes, Klebsiella pneumoniae, Pseudomonas 
aeruginosa, Escherichia coli, Staphylococcus aureus además del uso de 
cultivos convencionales.  
Resultados: Se reclutaron un total de 301 sujetos; 204 en GENDRES y 97 
en UK con una mediana de edad de 6.4 meses (primer cuartil: 2.2, tercer 
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cuartil: 17.0) en la cohorte GENDRES y 20.0 meses (primer cuartil: 7.0, 
tercer cuartil: 48.7) en UK. En ambas cohortes, el patógeno que se encontró 
más frecuentemente fue el VRS (52.9% y 36.1% muestras, 
respectivamente). Se encontró co-infección con múltiples virus en 92 
muestras (45.1%), y 29 muestras (29.9%) respectivamente; fue más 
frecuente en el grupo de edad de 12-48 meses. El patrón de co-infección 
observado más frecuente fue VRS-rinovirus (23 pacientes, 11.3%, cohorte 
GENDRES) y VRS-bocavirus/bocavirus-influenza (5 pacientes, 5.2%, 
cohorte UK). 
El patrón de co-infección no se correlacionó con ningún marcador de 
gravedad. Sin embargo, la sobreinfección bacteriana se asoció con un 
aumento en la gravedad (OR-“odds ratio”: 4.356; P-valor = 0.005), ingreso 
en UCIP (OR: 3.342; P-valor = 0.006), mayor puntuación en escala clínica 
(1.988; P-valor = 0.002), necesidad de soporte respiratorio (OR: 7.484; P-
valor < 0.001) y mayor estancia hospitalaria (OR: 1.468; P-valor < 0.001). 
Además, se encontró que la vacunación antineumocócica es un factor 
protector en términos del grado de dificultad respiratoria (OR: 2.917; P-valor 
= 0.035), ingreso en UCIP (OR: 0.301; P-valor = 0.011), menor valores en 
escalas clínicas (-1.499; P-valor = 0.021) necesidad de soporte respiratorio 
(OR: 0.324; P-valor = 0.016) y necesidad de oxígeno (OR: 0.328; P-valor = 
0.001). Todos los hallazgos se corroboraron en la cohorte de UK. 
Se incluyó un total de 66 niños que padecían infecciones respiratorias con 
VRS positivo. En un 10.6% de los pacientes se detectó presencia bacteriana 
en sangre, predominantemente H. Influenzae (n=4); S. pneumoniae (n=2). 
En estos pacientes con bacteremia existía una sospecha previa de 
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sobreinfección bacteriana en 6 de los 7 pacientes (85.7%). Se encontraron 
diferencias significativas en la gravedad de la enfermedad entre los niños 
con PCR bacteriana positiva o negativa: ingreso en UCIP (100% vs. 50%, P-
valor = 0.015); necesidad de soporte respiratorio (100% vs. 18.6%, P-valor < 
0.001); Score Wood-Downes (media=8.7 vs. 4.8 puntos; P-valor < 0.001); en 
la escala GENVIP (media = 17 vs. 10.1 P-valor < 0.001); y mayor estancia 
hospitalaria (media = 12.1 vs. 7.5 días; P-valor = 0.007). 
Conclusiones: Entre un tercio y dos tercios de los niños ingresados por 
IRAs de vías bajas están afectados por más de un virus, siendo 
particularmente frecuente en el segundo año de edad. La significancia 
clínica de estos hechos aun no está clara, pero no parecen tener un impacto 
clínico importante en términos de gravedad. Sin embargo, la sobreinfección 
bacteriana aumenta la gravedad del curso de la enfermedad. Por el 
contrario, la vacunación antineumocócica juega un papel protector. Por otro 
lado, la bacteremia no es frecuente en lactantes hospitalizados con una 
infección respiratoria por VRS, sin embargo, debe considerarse la posibilidad 
de una bacteremia oculta en los casos más graves. 

	  
RESUMO 
Introducción: As infeccións respiratorias son unha causa ben establecida 
da morbilidade e mortalidade infantil a nivel mundial, as cales estímase que 
causan o 75% das enfermidades agudas e son a causa principal de 
hospitalizacións en lactantes e nenos a nivel mundial. Non hai formas de 
tratamento e prevención a través da vacunación, agás para axentes 
específicos (gripe estacional e H1N1) e en individuos concretos con factores 
de risco. Con todo, a gran maioría das infeccións respiratorias ocorren en 
nenos aparentemente sans, sen antecedentes patolóxicos identificables, no 
que tamén a susceptibilidade, o curso clínico e prognóstico varían moito, 
mesmo sendo afectados polo mesmo virus. Dentro de este espectro, a 
infección por virus respiratorio sincitial (VRS) constitúe específicamente un 
dos paradigmas da infección respiratoria pediátrica, pola súa frecuencia, 
Abstract	  
XXXVIII 
morbimortalidade e a ausencia de medidas preventivas ou terapéuticas 
demostradamente eficaces. Mentras que as características clínicas das IRAs 
son fácilmente recoñecidas, o agente etiológico responsable da enfermidade 
é a menudo non detectado, xa que habitualmente usase a 
inmunofluorescencia como método de detección para VRS, virus influenza, 
parainfluenza e adenovirus. Neste sentido, a etioloxía da maioría das 
infeccións respiratorias crese que son virales, pero con este enfoque, só se 
identifica o virus en aproximadamente un 40% dos casos. 
Dende a introdución das técnicas de diagnóstico molecular a identificación 
de patóxenos que escapan a métodos convencionais aumentaron. Estas 
técnicas moleculares con frecuencia revelan a presenza de máis dun 
microorganismo nas mostras. A importancia destas co-infeccións na 
patoxenese, a gravidade ou o curso destas infeccións respiratorias non está 
ben establecida. Ademais, o risco de bacteremia en nenos con infección 
respiratoria viral e febre considerase tradicionalmente baixa. Nembergantes, 
a taxa concreta de bacteremia oculta en lactantes con infeccións por VRS 
non está ben establecida. 
Obxectivos: Os principais obxectivos do noso traballo foron: 1) analizar 
utilizando técnicas de diagnóstico molecular a epidemioloxía das co-
infeccións virais en nenos hospitalizados con IRA e evaluar a sua eventual 
influencia nas manifestacións clínicas e curso da enfermidade e 2) 
determinar a taxa actual e os factores predictivos de bacteremia evaluada 
por cultivos convencionais e por técnicas moleculares en nenos ingresados 
no hospital a causa dunha infección respiratoria aguda por VRS.  
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Métodos: Aplicouse un estudio multicéntrico, prospectivo, observacional 
usando a rede GENDRES (www.gendres.org). A rede clínica GENDRES foi 
creada no ano 2010 con fines investigadores para o estudio da influencia da 
xenética e da vitamina D nas infeccións respiratorias, coordinado desde o 
grupo de Xenética, Vacunas, Infeccións e Pediatría (GENVIP). Está formada 
por trece centros hospitalarios distribuidos por toda a península e máis de 
cincuenta investigadores colaboradores multidisciplinares. Ademáis, os 
resultados compararanse con unha cohorte de réplica de Reino Unido. Os 
nenos ingresados por infeccións agudas respiratorias en calquera dos 
hospitais de ambalas dúas redes entre os anos 2011-2013 foron elixibles 
para o estudio. Xunto ó estudio diagnóstico con técnicas convencionais 
aplicado no hospital de referencia, realizouse unha reacción en cadena da 
polimerasa (PCR) anidada e a tempo real para detectar o virus influenza (A 
and B), metapneumovirus, VRS, parainfluenza (1-4), rinovirus, adenovirus 
(A-F), bocavirus y coronavirus (NL63, 229E, OC43) a tódolos pacientes 
reclutados para o estudio. 
Ademáis, nos nenos que foran ingresados no hospital debido a unha IRA por 
VRS, evaluouse a presencia bacteriana en sangue para os organismos 
Meningococcus, Streptococcus pneumoniae, Haemophilus influenzae, 
Streptococcus pyogenes, Klebsiella pneumoniae, Pseudomonas aeruginosa, 
Escherichia coli, Staphylococcus aureus ademáis do uso de cultivos 
convencionais.  
Resultados: Reclutáronse un total de 301 suxeitos; 204 en GENDRES e 97 
en UK con unha mediana de idade de 6.4 meses (primeiro cuartil: 2.2, 
terceiro cuartil: 17.0) na cohorte GENDRES e 20.0 meses (primeiro cuartil: 
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7.0, terceiro cuartil: 48.7) en UK. Nas dúas cohortes, o patóxeno que se 
encontrou máis frecuentemente foi o VRS (52.9% e 36.1% mostras, 
respectivamente). Encontrouse co-infección con múltiples virus en 92 
mostras (45.1%), e 29 mostras (29.9%) respectivamente; foi máis frecuente 
no grupo de idade de 12-48 meses. O patrón de co-infección observado 
máis frecuente foi VRS-rinovirus (23 pacientes, 11.3%, cohorte GENDRES) 
e VRS-bocavirus/bocavirus-influenza (5 pacientes, 5.2%, cohorte UK). 
O patrón de co-infección non se correlacionou con ningún marcador de 
gravidade. Nembargantes, a sobreinfección bacteriana asociouse con un 
aumento na gravidade (OR-“odds ratio”: 4.356; P-valor = 0.005), ingreso en 
UCIP (OR: 3.342; P-valor = 0.006), maior puntuación na escala clínica 
(1.988; P-valor = 0.002), necesidade de soporte respiratorio (OR: 7.484; P-
valor < 0.001) e mayor estancia hospitalaria (OR: 1.468; P-valor < 0.001). 
Ademáis, encontrouse que a vacunación antineumocócica é un factor 
protector en términos do grado de dificultad respiratoria (OR: 2.917; P-valor 
= 0.035), ingreso en UCIP (OR: 0.301; P-valor = 0.011), menor valor na 
escala clínica (-1.499; P-valor = 0.021) necesidade de soporte respiratorio 
(OR: 0.324; P-valor = 0.016) e necesidade de oxíxeno (OR: 0.328; P-valor = 
0.001). Todos os achamentos corroboraronse na cohorte de UK. 
Incluíronse 66 nenos que padecían infeccións respiratorias con VRS 
positivo. Nun 10.6% dos pacientes detectouse presencia bacteriana en 
sangue, predominantemente H. Influenzae (n = 4); S.pneumoniae (n = 2). 
Nestos pacientes con bacteremia existía unha sospeita previa de 
sobreinfección bacteriana en 6 dos 7 pacientes (85.7%). Encontraronse 
diferencias significativas na gravidade da enfermidade entre os nenos con 
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PCR bacteriana positiva ou negativa: ingreso en UCIP (100% vs. 50%, P-
valor = 0.015); necesidade de soporte respiratorio (100% vs. 18.6%, P-valor 
< 0.001); Score Wood-Downes (media = 8.7 vs. 4.8 puntos; P-valor < 0.001); 
na escala GENVIP (media = 17 vs. 10.1 P-valor < 0.001); e maior estancia 
hospitalaria (media = 12.1 vs. 7.5 días; P-valor = 0.007). 
Conclusiones: Entre un tercio e dous tercios dos nenos ingresados por 
IRAs de vías baixas están afectos por máis dun virus, sendo particularmente 
frecuente no segundo ano de idade. A significancia clínica destos feitos 
ainda non está clara, pero non parece ter un impacto clínico importante en 
términos de gravidade. Poren, a sobreinfección bacteriana aumenta a 
gravidade do curso da enfermidade. Polo contrario, a vacunación 
antineumocócica xoga un papel protector. Por outro lado, a bacteremia non 
é frecuente en lactantes hospitalizados con unha infección respiratoria por 
VRS, nembargantes, débese considerar a posibilidade dunha bacteremia 
oculta nos casos máis graves. 
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1 INTRODUCTION 
1.1 Acute Respiratory Infection  
Definition  
Acute respiratory infection (ARI) includes all types of infection of the 
respiratory tract with multitude of signs and symptoms. It is usually 
characterised by cough or wheeze, with or without the presence of fever, 
acute rhinitis and rhinorrhea, pharyngitis and respiratory distress.  
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Burden of the disease 
ARIs are estimated to cause 75% of all acute illness and are the leading 
cause of hospitalization for infants and young children worldwide [1,2]. The 
burden of the diseases for ARIs is estimated at 3.9 million deaths (WHO, 
2002) [3] and are among the leading causes of death in children under five 
years old [2,4,5]. In addition to producing significant morbidity in the short 
term, some viral ARIs acquired early in life have been related to increased 
risk of illness as asthma years after the infection [6]. 
 
Figure 1. Child mortality rates by cause and region, 2004 (WHO) 
 
Etiology 
Viruses are responsible for most infections in children and adults [1,7] 
including respiratory syncytial virus (RSV), influenza virus (IV), human 
parainfluenza virus (hPIV), adenovirus (AdV) and rhinovirus (hRV). In the 
past decade, several new respiratory viruses, including human 
metapneumovirus (hMPV) [8], new subtypes of human coronaviruses (hCoV) 
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[1] and bocavirus (hBoV) [9], have been associated with ARI, though their 
clinical importance requires clarification. 
While the clinical features of ARIs are easily recognized, the etiological agent 
responsible for disease is not often detected with non-molecular diagnostic 
techniques, which typically use direct immunofluorescence to detect RSV, IV, 
hPIV and AdV. Although the etiology of most lower respiratory tract infection 
is thought to be viral, specially in younger children, a virus is identified in 
approximately 40% of cases with this approach [10]. 
Epidemiology 
• Age groups  
All age groups are affected by ARIs, although the infants or young children 
are most likely to suffer severe disease and require hospital admission. In 
this regard, infections of the respiratory tract are a common problem in the 
first decade of life. The yearly prevalence of ARI in an otherwise healthy 3-
year old child is about three to ten infections [11] and among the causes of 
death, only respiratory tract infections are a leading cause of death in 
newborn and older children [12].  
• Seasonal Distribution  
ARIs arise throughout the year, however they are more prevalent in the 
autumn and especially in winter months. This is because the respiratory 
viruses have a strong seasonality, peaking in the winter months in temperate 
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climates, and in the wetter months in tropical climates, with very few 
infections being detected in the summer months. In pediatric patients and 
particularly in children under one year of age this strong peak incidence in 
the winter months is particularly remarkable due to the high risk of 
hospitalization. 
Risk Factors  
Risk factors for ARI can be divided into clinical and demographic factors. 
Clinical risk factors include: prematurity; low birth weight; co-existing cardiac 
or respiratory problems; immunodeficiency and birth during the first half of 
the season. Demographic risk factors include the male sex, a lack of 
breastfeeding; multiple siblings/crowded living conditions; a low 
socioeconomic status and smokers in the household [13,14]. 
Clinical Manifestations and Management of ARI  
The term ‘acute respiratory infection’ includes all infections of the respiratory 
tract, from a mild upper respiratory tract infection (URTI) to bronchiolitis or 
pneumonia. Diagnoses are usually made on clinical grounds and the majority 
of children with ARI will have a mild, self-limiting illness and do not require 
any treatment. However, ARI can cause very severe infections, especially in 
the younger children and those with other co-morbidities, leading to many 
hospital admissions especially during winter season. The core treatment is 
supportive, and includes the use of supplemental fluids and oxygen. 
1. Introduction	  
5 
 
Figure 2. Respiratory system and main disorders 
 
• Upper Respiratory Tract Infection  
URTI are very common and usually mild and self-limiting, with the common 
cold being the most common manifestation. The common cold requires 
supportive treatment, making sure that the child is kept well hydrated, and 
the use of anti-pyretics in the presence of fever. Other manifestations 
classed as URTI include acute otitis media (AOM), croup, whooping cough 
and epiglottitis.  
• Lower Tract Respiratory Infection 
Lower tract acute respiratory infections (LT-ARI) are those diseases below 
the level of the larynx, so it affects to the trachea and lungs. According to the 
part of the respiratory tract that is affected include: bronchiolitis or bronchitis, 
pneumonia and bronchospasm. 
Common%cold%
(viral%rhini/s)%
Nasal%membranes%swell%
and%produces%mucus%
Pneumonia%
Alveoly%in%the%lungs%become%inflamed,%
red,%and%flooded%with%fluid%
Bronchi/s%
The%bronchi%become%inflamed%
and%irrited%because%of%an%
infec<on,%usually%viral%
Bronchioli/s%
inflamma<on%of%the%bronchioles.%
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• Bronchiolitis 
The term bronchiolitis refers to the inflammation of the bronchioles, although 
these findings are rarely observed directly and inferred in a young child who 
presents respiratory distress in association with signs of viral infection. In 
1983 clinical criteria for defining bronchiolitis were established by 
McConnochie as the first acute episode of wheezing in children younger than 
24 months, expiratory dyspnoea and existence of prodromal catarrhal [15]. 
However, definitions of bronchiolitis may vary in the different studies, and in 
recent years researchers have attempted to homogenize the population of 
children with bronchiolitis by limiting to infants under twelve months with a 
first-time episode of wheezing [16]. 
Acute bronchiolitis is the most frequent low respiratory tract infection in 
infants and is a significant health care demand, not only in primary care, 
where it generates a sizeable number of medical visits, but also in hospitals 
with large attendance requirements in the emergency room and large 
number of admissions in epidemic periods. Bronchiolitis is the most common 
cause of hospitalization, and 90% of these cases requiring hospitalization 
occur in children under twelve months of age [13,17] with incidence peaks at 
age three to six months [18]. Its annual incidence is 10% and the admission 
rate between 2 – 5% [19], with an important increment in the last few years. 
Between 5 – 16% of the admissions will require pediatric intensive care unit 
(PICU) attendance. Although the bronchiolitis morbidity is high, deaths in 
industrialized countries from respiratory syncytial virus infection have been 
estimated generally as less than 500 per year, and most of these fatal 
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infections occur among children with co-morbid cardiopulmonary conditions 
[18]. It was estimated that in Spain the annual average cost for National 
Health Care System for bronchiolitis requiring hospitalization was €47 M with 
a mean hospitalization costs of €2162 in children up to five years old [20]. 
The course of bronchiolitis is variable and ranges from temporary events, to 
progressive respiratory distress from lower airway obstruction. The viral 
infection occurs through the upper respiratory tract and spreads to the lower 
within a few days, resulting in inflammation of the bronchiolar ephitelium, with 
peribronchial infiltration of white cells (mononuclear cells mostly) and 
oedema of the submucosa and adventia. The cause of the partial or total 
obstruction to airflow is the necrotic epithelium and fibrin in the airways.  
 
Figure 3. Bronchiolitis physiopathology (medicsindex.ning.com) 
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The main clinical features are initial rhinitis and coryza, developing into 
cough, and may progress to wheezing and/or crackles and signs of 
respiratory distress, manifested as tachypnea, nasal flaring, hyperinflation 
and intercostal and/or subcostal retraction [21,22].  
The core of treatment for bronchiolitis, as it is a viral infection, remains 
supportive. In the clinical practice, oxygen is usually given if oxyhemoglobin 
saturations are below 90%, if the child has severe respiratory distress or if 
the child is cyanosed. Additionally, adequate nutrition and hydration should 
be maintained, and if this is not possible through oral feeding, nasogastric 
feeding or the use of intravenous fluids should be considered [21].  
Many studies have investigated the use of corticosteroids and 
bronchodilators in bronchiolitis, and although both may improve short-term 
clinical parameters, there is little evidence and a lot of controversy supporting 
the use of both of them [21]. 
• Pneumonia 
Pneumonia describes an infectious process resulting from the invasion and 
overgrowth of microorganisms in lung parenchyma, breaking down defenses 
and provoking intra-alveolar exudates.  
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Figure 4. Alveoli changes in pneumonia (www.vtherm.com) 
 
Despite significant reductions in child mortality over the last decade, 
pneumonia remains the leading cause of childhood mortality worldwide, 
accounting for 18% of deaths in children under the age of five. In this range 
of age, an estimated 1.1 million children are fatality cases every year due to 
pneumonia, more than acquired immune deficiency syndrome, malaria and 
tuberculosis cases combined [23,24].  
 
Figure 5. a) Deaths in children less than five years of age (Source: WHO/UNICEF: End preventable 
deaths: Global Action Plan for Prevention and Control of Pneumonia and Diarrhoea. b) Global trends in 
burden of childhood deaths in 2000–2010 (Source: Liu et al. 2012) 
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The clinical symptoms in children diagnosed by pneumonia include fever, 
tachypnoea and respiratory distress, often with focal or diffuse crackles on 
auscultation. Chest X-ray are usually performed to support clinical grounds. 
The etiology of pneumonia varies significantly depending on the age of the 
patient [25]. Respiratory viruses are the most frequent pathogens in children 
aged between four months and five years (with RSV and rhinovirus the main 
viruses), and are responsible for approximately 40% of the community-
acquired pneumonia episodes in hospitalised children. S. pneumoniae is 
reported in one-third of the cases of all ages, and Mycoplasma pneumoniae 
is the main pathogen in children aged 5 - 15 years [26]. 
Treatment of pneumonia is empirical, due to the absence of reliable markers 
capable of distinguishing viral and bacterial pneumonia [25]. In viral 
pneumonia, only supportive treatment is recommended. 
• Bronchospasm 
Bronchospasm or bronchial spasm is the abnormal and abrupt contraction of 
bronchial smooth muscles. It is considered to be mediated by release of 
substances from mast cells or basophils as inflammatory mediators, 
chemokines and cytokines and alterations in mechanical load [27]. Typical 
symptoms associated with acute bronchospasm include cough, wheezing, 
and chest tight-ness and it causes difficulty in breathing which can be very 
mild to severe. Bronchospasm are caused by a number of reasons. Triggers 
can include environmental exposures and allergens or lower respiratory tract 
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diseases such as pneumonia, asthma, chronic obstructive pulmonary 
disease (COPD), and even physical activity [28].  
Indicators of disease severity  
Perhaps, more important than labelling a condition is the ability to recognise 
the more severe disease, or the prognostic to more severe disease. The 
reasons for hospitalization in illnesses as bronchiolitis are often subjective so 
it is important to recognise the more severe diseases or factors that have the 
ability to increase the disease severity. On this way, and although there is 
controversy on its utility, oxygen saturations derived from the non-invasive 
method pulse oximetry are the single predictor of severe disease in 
bronchiolitis [29]. In patients with pneumonia, as we mention previously, a 
chest X-ray is also performed to see if there is evidence of consolidation. 
Special attention should be paid to patients with other comorbidities or with 
recurrent wheezing, as they are at high risk of complications. 
Although the immediate morbidity and mortality associated with LT-ARI 
comes from the acute illness, some investigators postulated the association 
between viral infection in infancy or childhood with respiratory problems later 
in life, such as recurrent wheeze and asthma.  
1.2 Viral infection  
Respiratory tract infections are caused clinically by a multitude of pathogens, 
but viruses are the main causative agents [10]. Moreover, pathogen-specific 
clinical symptoms are often lacking. The respiratory agents described below 
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is not intended as a complete list of all agents that cause acute respiratory 
tract infections, and some of the viruses described may cause symptoms 
outside of the respiratory tract. The description of each virus below focus on 
the respiratory illness they cause. 
Virus: definition and general characteristics 
A virus is an infectious agent that only replicates inside the living cells of 
other organisms. Viruses can infect all types of life forms, from animals and 
plants to bacteria and archaea. 
A complete virus particle is known as a virion. Consist of two or three parts:  
• Genetic material: either DNA or RNA 
• Protein coat creating a capsid that protects the genes. 
• In some cases, an envelope of lipids encloses the protein coat. This is 
derived from the host cell membrane.  
 The shapes of viruses range from simple helical and icosahedral forms to 
more complex structures (Figure 6).  
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Figure 6. Basic characteristics of RNA and DNA virus (www.nlv.ch). 
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• Virological characteristics 
Taxonomic characteristics of the main virus found in ARI are described in the 
following table: 
Virus Family Genome Sub-/serotypes 
RSV Paramyxoviridae (–) ssRNA  
linear 
Subtypes A and B 
Rhinovirus Picornaviridae (+) ssRNA  
linear 
Species A to C, > 100 
serotypes 
Influenza Orthomyxoviridae (–) ssRNA 
linear/segmented 
A, B, C 
Adenovirus Adenoviridae dsDNA  
linear 
> 50 serotypes 
Metapneumovirus Paramyxoviridae (–)ssRNA  
linear 
Subtypes A and B 
Parainfluenza Paramyxoviridae (–)ssRNA  
linear 
Serotypes 1–4 
Coronavirus Coronaviridae (+)ssRNA  
linear 
229E, OC43, NL63, 
HKU1, MERS, SARS 
Bocavirus Parvoviridae (+) and (–) 
ssDNA linear 
Serotypes 1–4 
 
Table 1. Taxonomic characteristics of respiratory virus 
Respiratory Syncytial Virus  
• History of RSV 
The respiratory syncytial virus (RSV) gets its name from its ability to cause 
fusion between the membranes of nearby syncytia cells. It was first isolated 
in 1956 by Morris et al. [30] in a group of chimpanzees who had coryza, and 
they named the virus Chimpancee Coryza Agent. The following year, in 
1957, Chanock and his team [31] in Baltimore (USA), isolated the same 
agent in two children diagnosed with pneumonia and stridulus laryngitis, 
being called from that time RSV. In Spain the first isolate was reported by 
Pumarola in 1967. 
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• Virology of RSV 
Based on the virological classification, RSV is categorized within the family 
Paramyxoviridae with such well-known viruses such as measles, mumps and 
the paramyxovirus and is classified in the genus Pneumovirus [32]. RSV has 
a single negative strand of non-segmented RNA (Figure 7), which is 
important because the virus does not reassort with other viruses as influenza 
or rotavirus do [33]. 
  
Figure 7. Schematic diagram of RSV [34] 
  
It is an enveloped virus medium size (120-300 nm) with glycoprotein 
projections of 12 nm in length (15222 nucleotides) which encodes the 
synthesis of 11 viral proteins: three transmembrane glycoproteins known as 
the attachment glycoprotein (G), the fusion protein (F), and the small 
hydrophobic protein (SH); one matrix protein (M); two transcription factors 
(M1 and M2); three proteins associated with the nucleocapsid (N, P, and L); 
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and two non-structural proteins (NS1 and NS2) [32]. The F and G 
glycoproteins are the main surface antigenic determinants and they stimulate 
the production of protective host immune responses (Figure 8). 
• G protein: It is a type II transmembrane protein with an N-terminal 
cytoplasmic domain, a hydrophobic fix region and a highly variable 
ectodomain. Many of the epitopes recognized by the host antibody 
response lie in the C terminal variable regional [35]. 
• F protein: It is a highly conserved protein among the Paramyxoviridae 
family and is a very important protein for RSV because of the fusion of 
the viral envelope or infected cell membranes with uninfected cell 
membranes. The part of the F protein that enters the cell membrane is 
situated at the N terminal region [35]. 
 
Figure 8. Schematic genome and proteins of the RSV. 
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• Subtypes of RSV 
Human RSV isolates can be classified into two major groups, A and B, each 
containing several distinct subgroups. This classification is based upon 
antigenic and genomic differences found in several viral proteins, but 
specially the G protein [33]. The two major strain groups circulate 
simultaneously during an outbreak, although group A viruses are more 
prevalent (Table 2). The dynamics of annual epidemics appear to be local 
rather than national or global [36]. 
Protein Nucleotide Amino acid sequence 
F 79% 89% 
G 67% 53% 
 
Table 2. Nucleotid and amino acid sequence homology between group A and B. 
• Genetic diversity of RSV 
RSV has a non-segmented RNA genome. Thus, it does not have the 
capacity for reassortment of genome segments, the process by which 
influenza viruses undergo antigenic shifts leading to influenza virus 
pandemics. However, as with other RNA viruses, RSV has a quite mutable 
genome by virtue of its dependence on an RNA polymerase that lacks the 
capacity of RNA proofreading and editing. The main antigenic and genetic 
differences between RSV groups A and B were found in the attachment 
glycoprotein G. Variability in this protein is greater than that in the other 
proteins, and consequently contributes to the ability of the virus to cause re-
infections and annual epidemics [37]. 
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• Epidemiology of RSV 
RSV infection is a very prevalent illness. The WHO-estimated global annual 
infection and mortality data for human RSV are 64 million and 160.000, 
respectively. Furthermore, about 90% of infants and young children by the 
age of two years are affected and peak rates occur in infants aged 6 weeks 
to 6 months. 
RSV is responsible for approximately 50% of all pneumonia and up to 90% of 
the reported cases of bronchiolitis in infancy. In industrial countries, infants 
and young children RSV infection is recognized as the leading cause of 
hospitalization and in hospitalized infants with RSV bronchiolitis, mechanical 
ventilation is required in 7 - 21% of the cases [38]. One large study found 
RSV to be responsible for 20% of hospitalizations, 18% of emergency 
department visits and 15% of general practitioner visits in children under five 
with ARI in the United States. It is also thought to be responsible for 50 - 90% 
of hospitalisations for bronchiolitis. 
•  Immunopathogenic aspects of RSV 
The incubation period of RSV is estimated to be five days. Respiratory tract 
inflammation in RSV bronchiolitis is a multicellular process in which epithelial 
cells, macrophages, cytotoxic T cells and eosinophils are implicated [33]. 
 At the beginning of the infection, the virus replicates in the nasopharynx 
epithelial cells and cytokines are secreted by macrophagues [33]. During 
bronchiolitis, ciliated epithelial cells are destroyed. In its severe form, the 
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disease involves peribronchiolar mononuclear cell infiltrates accompanied by 
submucosal edema and bronchorrhea [39] (Figure 3). 
• Spread of the RSV 
The virus is primarily spread through large particle aerosols (due to coughing 
or sneezing) or by fomites followed by self-inoculation. RSV can survive on 
non-porous surfaces for 6 – 7 hours, porous surfaces for 2 hours, and the 
skin for 20 – 30 minutes. These characteristics make transmission relatively 
probable among children and infants in close contact with each other [40]. 
• Clinical manifestations of RSV 
Clinical manifestations vary based on patient age and on whether the 
infection is primary or secondary [41]. In infants, lower respiratory tract signs, 
such tachypnea, wheezing, or rales, usually appear 1 to 3 days after the 
onset of rhinorrhea, representing viral spread into the bronchi and 
bronchioles. RSV infection starts with a short course of upper respiratory 
symptoms. Increased respiratory rate, intercostal and subcostal retractions, 
and difficulty in feeding characterize the lower airway disease. Prolonged 
expiration, with or without wheezing, and audible crackles during inspiration 
are characteristic of bronchiolitis. The typical radiographic features are air 
trapping, peribronchial patchy infiltrates, and segmental atelectases. Thus, 
bronchiolitis shares common features with viral pneumonia and in fact only 
represent different phases of the same disease [42]. 
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• RSV Risk Factors 
Some predisposing factors for severe RSV disease have been identified 
(Table 3). However, risk factors for severe infection cannot completely 
explain differences in disease severity, and the majority of patients 
hospitalized for severe RSV disease do not fit the profile of high-risk patient 
[43]. 
 
Children at risk for severe RSV infection 
Young age  < 2 months (term infants) 
Premature birth ≤ 34 weeks 
Lack of breastfeeding [19] 
Chronic disorders: bronchopulmonary dysplasia, congenital heart 
disease, cystic fibrosis and immunosupressed patients. 
Environmental factors [44]: Tobacco smoke exposure, outdoor air 
pollution, low socioeconomic status, crowded living conditions, 
malnutrition. 
 
Table 3. Children at risk for severe RSV infection 
 
Rhinoviruses  
Human rhinovirus (hRV) was first discovered in the 1950s studying the 
etiology of the common cold, and at the beginning it was thought to be not a 
very severe infectious agent just causing URTI. Nowadays, studies have 
correlated the hRV with bronchiolitis or asthma exacerbations and wheezing 
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hospitalizations [45]. 
hRV is a member of the family Picornaviridae and the genus Enterovirus. It is 
a positive-sense, single-stranded-RNA virus of approximately 7,200 bp and is 
classified into three species, hRV-A (74 serotypes); hRV-B (25 serotypes) 
and hRV-C. The hRV structure is composed by a capsid, which protects the 
RNA, is composed of 60 copies of each of 4 structural proteins (Figure 9).  
 
Figure 9. Schematic genome and proteins of hRV [46]. 
 
Virus protein 1 (VP1), VP2, and VP3 are located on the capsid surface and 
are responsible for its antigenic diversity while VP4 is located inside the 
capsid and attaches the RNA core to the viral capsid. 
• Epidemiology of hRV 
An initial work has shown hRV have optimum replication temperatures of 
33ºC – the temperature in the nasal passages, as contrasting to the higher 
temperatures in the lower respiratory tract, another factor in support of hRV 
being associated with URTI and the common cold. However, further research 
has shown that although the optimum temperature for hRV replication is 
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33ºC, they are still able to replicate effectively at 37ºC, proving it is feasible 
that they are a cause of LT-ARI [47]. 
The prevalence of hRV bronchiolitis was described in approximately 20 – 
40% in emergency department and hospitalized patients. Rhinoviruses have 
been found to cause about two-thirds of common colds and asthma 
exacerbations in adults and older children.  
Since the introduction of molecular methods of viral detection, hRV has 
frequently been found in asymptomatic children. This detection has 
established controversy to the clinical utility of the molecular techniques and 
it was postulated that these findings might be due to:  
i) A past and resolved respiratory illness with prolonged virus 
shedding; hRV was detected in children even 15 days after the 
respiratory illness. 
ii) Mild or diffuse symptoms. 
iii) The incubation period prior to the onset of symptoms. Rates of 
asymptomatic infection described range from 12 to 32% in children 
under four years old. 
Adenovirus  
Adenovirus was first isolated in 1953 in cells culture of human adenoids [48]. 
It is a member of the family Adenoviridae and is a linear double stranded 
DNA virus with a terminal protein, medium-sized (90 – 100 nm), with an 
icosahedral nucleocapsid and nonenveloped virus (without an outer lipid 
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bilayer). Adenovirus (AdV) infection can be classified according to over 50 
different serotypes, which are included in seven species (A - G) [49].  
AdV typically cause mild and self-limited infections involving the upper or 
lower respiratory tract, gastrointestinal tract, or conjunctiva [49,50]. AdV 
infection of the respiratory tract can lead to a wide spectrum of disease from 
mild upper respiratory tract symptoms to severe pneumonia, with one 
particular serotype (serotype 14) being associated with particularly severe 
disease and a high mortality rate. Up to 10% of LT-ARIs in pediatric 
population are caused by AdVs and infections are more common in young 
children, aproximately an 80% of AdV infections occur in children <4 years 
old [51]. 
• Structure of AdV 
Adenoviruses are nonenveloped, icosahedral particles about 90 nm in 
diameter with fibers projecting from the vertices of the icosahedrons. The 
DNA is linear, double-stranded and nonsegmented. The outer structure of 
the virus is comprised of 240 hexons and 12 pentons at vertices of the 
icosahedron. Adenovirus fibers of species-specific lengths extend from the 
penton and are associated with hemagglutination properties 
Parainfluenza Viruses  
Parainfluenza viruses (hPIV) are large (150 - 200nm in diameter) enveloped 
RNA viruses with a genome encompassing ≈ 15,000 nucleotides belonging 
to the Paramyxoviridae family. hPIV have been designated into five subtypes 
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(type 1-3, 4a and 4b) that cause human disease, and hPIV 1-3 are the most 
significant in humans. All known human hPIV were isolated in the second 
half of the 1950s [52]. 
hPIV are common causes of ARI, especially in children, with studies 
estimating that most children will have evidence of infection with multiple 
serotypes by the age of five. Most hPIV infections are limited to the upper 
respiratory tract, with up to 50% complicated by AOM, and only 15% 
involving the lower respiratory tract [52]. 
 
Figure 10: a) Schematic parainfluenza virion b) Schematic illustration of the parainfluenza life cycle 
[53]. 
Abbreviations: HN, Hemagglutinin-neuraminidase protein, RER, rough endoplasmic reticulum; hPIV, 
human parainfluenza virus; L, large RNA polymerase protein; M, matrix protein; NP, nucleocapsid 
protein; P, phosphoprotein 
 
The clinical diseases caused by hPIVs include rhinorrhea, cough, croup 
(laryngotracheobronchitis), bronchiolitis, and pneumonia. hPIV-3 is the most 
common type, as seen in studies of children. Clinical manifestations are 
broad, but most result in an URTI, although a significant number  (30 – 50%) 
are associated with AOM [52,54]. About 15% of hPIV infections cause LRTIs; 
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hPIV-1 being associated with croup, and hPIV-2 and hPIV-3 with 
bronchiolitis. As with many other respiratory viruses, hPIV can cause severe 
disease in immunocompromised hosts [52]. 
Influenza Virus 
Influenza (IV) is a RNA virus classified in the family Orthomyxoviridae and 
three antigenic types of IV have been identified: A, B and C. All of them are 
causative agents for respiratory infections, but the main differences regarding 
the clinical course of the illness caused between them is the severity of the 
disease and the prevalence. Influenza A frequently causes more severe and 
pandemic illness, while influenza B and C have caused illness of epidemic 
proportion. The principal reason is that Influenza A has the ability of being 
high mutagenic while Influenza B does not experience as much antigenic 
changes so it causes only a minority of seasonal influenza cases each year. 
Influenza C is usually associated with minor symptoms. 
• Epidemiology of IV 
Influenza is an infection that spreads easily from person to person and the 
WHO estimated an annual attack rate at 5% – 10% in adults and 20% – 30% 
in children. Symptoms can be mild to severe, and on this regards, the 2014 
annual epidemics were estimated to result worldwide in about 3 to 5 million 
cases of severe illness, and about 250 000 to 500 000 deaths. 
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• IV Risk factors 
Influenza illnesses can result in hospitalization and death mainly among high-
risk groups: 
− Age: children younger than two years of age and elderly  
− pregnant women 
− certain medical condition such as chronic heart, lung, kidney, liver, 
blood or metabolic diseases (such as diabetes), or debilitated immune 
systems. 
• Influenza A pandemics 
For Influenza pandemics occur (Table 4), two conditions have to take place: 
1) to emerge in the humans an influenza virus with a hemagglutinin against 
which there is weak or no existing immunity; 2) spreads easily from human-
to-human.  
Name of pandemic Date Subtype involved 
1889–1890 flu pandemic (Asiatic/Russian 
Flu) 
1889–1890 possibly H3N8 or 
H2N2 
1918 flu pandemic (Spanish flu) 1918–1920 H1N1 
Asian Flu 1957–1958 H2N2 
Hong Kong Flu 1968–1969 H3N2 
Russian flu 1977–1978 H1N1 
2009 flu pandemic 2009–2010 H1N1 
 
Table 4. Influenza pandemics throughout the history. 
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Since 2009, a new reassorted A/H1N1 virus had circulated worldwide among 
humans, causing morbidity and mortality, and was referred to as a pandemic 
H1N1. 
Coronaviruses 
Tyrell and Bynoe identified the first human coronaviruses in the 1960s. 
Phylogenetic analysis grouped the Coronaviruses into the order Nidovirales, 
family Coraviridae, belonging to one of two subfamilies: Coronavirinae and 
Torovirinae. They are enveloped viruses with a positive-sense RNA genome 
(27.000 a 30.000 bases) and with a nucleocapsid of helical symmetry. The 
genomic size of coronaviruses ranges from approximately 26 to 32 kilobases.  
 
Figure 11: Schematic representation of the hCoV  
 
Four human coronaviruses (HCoV-229E, HCoV-OC43, HCoV-NL63 and 
HCoV-HKU1) are endemic in the human population and are mainly 
associated with mild, self-limiting respiratory illnesses. In this regards, hCoV 
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is the second cause of common cold (the first one is Rhinovirus, as said 
previously) and mainly affects toddlers and children. hCoV infects epithelial 
cells and generally the infection remains localized in the upper respiratory 
tract due to the optimal temperature to virus proliferation is 33 - 35ºC (see 
replication of hCoV in figure 12). However, this four hCoV can also present 
with high morbidity outcomes of the lower respiratory tract including 
bronchiolitis and pneumonia [55,56]. 
Another two human coronaviruses, namely SARS-CoV and MERS-CoV 
cause severe respiratory syndromes and present a significant risk with their 
high fatality rates. Severe associated respiratory syndrome (SARS)-
associated coronavirus was identified in 2002 firstly in the south part of 
China, which had particularly severe clinical manifestations, with some 
patients developing respiratory distress syndrome, requiring intensive care 
and ventilation. In June 2012 the most recent emergence of a completely 
novel strain of human coronavirus was identified (MERS-CoV) [57]. 
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Figure 12: Schematic illustration of the coronavirus life cycle (www.wikipedia.org) 
	  
Human metapneumovirus  
The team of Proffesor Osterhaus discovered the human metapneumovirus 
(hMPV) in 2001 in Netherlands [8]. It is a RNA virus belonging to the 
Paramyxoviridae family, subfamily Pneumovirinae and two main groups, A 
and B, have been identified. Both antigenic subtypes usually circulate 
concurrently every year being humans the single source of infection. The 
incubation period is estimated in 3 - 5 days and the duration of viral 
clearance in otherwise healthy children is about 1 - 2 weeks.  
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• Structure of hMPV 
hMPV virions were visualized by electron microscopy as pleomorphic 
spheres and filaments that were reported to have general similarity to those 
of RSV. hMPV is an enveloped, single stranded negative sense RNA virus 
that consists of 13,350 nucleotides, and nine proteins, comprising the N 
(nucleoprotein), P (phosphoprotein), M (matrix protein), F (fusion protein), M2 
(matrix proteins M2-1 and M2-2), SH (small hydrophobic protein), G 
(glycoprotein) and L (RNA-dependent RNA polymerase) genes. The M2 
gene contains two open reading frames and encodes the M2-1 and M2-2 
proteins [58] (Figure 13). 
 
Figure 13: A schematic representation of the differences between Metapneumovirus and RSV is 
represented. Genes are represented as boxes with the corresponding encoded protein [58]. 
• Epidemiology of hMPV 
hMPV is a main cause of LT-ARI in infants and children worldwide. The most 
common presentation of hMPV in children includes complications of the 
upper respiratory tract but hMPV causes a clinical spectrum of illness from 
upper airway infection to severe lower respiratory tract infections. 
Bronchiolitis, pneumonia, croup and asthmatic exacerbations are the most 
frequently associated lower respiratory tract complications [59]. hMPV and 
has been shown to play a major role in respiratory infections, being found in 
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7 - 19% of samples from children with ARI [59]. It is a very prevalent virus, 
serological studies indicate that all children at the age of five were infected at 
least once by hMPV and recurrent infections may occur during all ages. This 
may be due to insufficient immunity acquired during the initial infection and/or 
due to infection by different viral genotypes. The incubation period varies 
from individual to individual, but is commonly between 3 and 5 days [58]. 
Human Bocavirus  
Allander et al. [9] reported in 2005 the discovery of a previously undescribed 
human parvovirus in respiratory secretions from children with respiratory tract 
disease with unknown etiology in Sweden. It was discovered by molecular 
virus screening which is based on random cloning and bioinformatical 
analysis. Phylogenetic analysis grouped the hBoV into the family 
Parvoviridae, subfamily Parvovirinae, and genus Bocavirus. Up to the date, 
four subtypes have been identified, hBoV 1 - 4. Of these, hBoV1 is most 
frequently detected in clinical samples of the respiratory tract and the 
remaining isolates are more frequently associated with gastrointestinal 
infections and symptoms [60]. Its genome is a linear, single-stranded DNA 
5.2 - 5.3 kilobases in length with terminal hairpin structures at both ends. 
• Epidemiology of hBoV 
hBoV was detected in 1.5% – 18.3% of respiratory samples from individuals 
with ARIs, especially those from young children and infants [61]. In Spanish 
children, Garcia-Garcia et al. [62] found applying a PCR technique that a 
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17.1% of the patients hospitalized for respiratory infections were positive in 
hBoV. This virus can be detected not only in respiratory samples but also in 
blood, urine, and stools [61]. The seroprevalence of HBoV is strongly 
dependent on the age of the investigated patient cohort and ranges from 
40% in children between 18 and 23 months of age up to virtually 100% in 
children older than two years. In contrast to other viruses, hBoV has been co-
detected with other pathogens than any other respiratory virus [63]. 
1.3 Bacteremia 
Definition 
Bacteremia is the presence of viable bacteria in the circulating blood. The 
detection of bacteria in the blood is always abnormal as blood is a sterile 
environment. It is most commonly accomplished by blood cultures.  
Bacteremia is different from sepsis, which is a condition where bacteremia is 
associated with an inflammatory response from the body (causing systemic 
inflammatory response syndrome, characterised by rapid breathing, low 
blood pressure, fever, etc.) 
Bacteremia in respiratory infections 
The main complication of viral respiratory infections is bacterial co-infection 
and the synergism established between virus and bacteria have been widely 
discussed in the literature, particularly for respiratory viruses and secondary 
bacterial pneumonia [64]. Bacteremia rates reported in children with 
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respiratory illness are low, with rates <1.2% in RSV confirmed cases [65-69]. 
In those requiring mechanical ventilation bacterial co-infection rates may 
vary, with much higher rates, ranging from 21.0% to 43.9%. However, the 
risk of bacteremia with pathogenic bacteria in the setting of acute RSV 
infection in infants with no other risk factors as well as the impact of this 
bacteremia in the severity of the respiratory disease is still unclear. 
1.4 Techniques 
For the viral diagnosis in respiratory illness, different methods can be used 
either by the detection of the virus or parts of the virus or identifying the 
immune response developed by the infected individual: virus isolation, 
antigen detection, genome detection and serology. The differences between 
them are the cost, time-requirement and sensitivity and specificity. 
In this regard, the wider availability of molecular diagnosis techniques has 
allowed the identification of pathogens otherwise missed using conventional 
modalities, frequently detecting more than one microorganism but the 
importance of co-infections in the pathogenesis, severity or course of 
respiratory infections is not well established. In children with ARI, the 
confirmation frequency of pathogens may exceed 80% [70]. Contrary, the 
high sensitivity of molecular techniques raises questions about the clinical 
relevance of positive test results. 
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Direct immunofluorescence 
Immunofluorescence is a common laboratory technique used both in 
research and clinical diagnostics, developed by Coons in the early 1940s. 
This technique uses an antibody chemically linked to a fluorophore that 
recognizes the virus antigen. The signal emitted by the fluorophore can then 
be quantified by different techniques: flow cytometer, array scanner or 
automated imaging instrument, or visualized using fluorescence or confocal 
microscopy [71]. 
 
Figure 14: Schematic of the direct immunofluorescence technique 
(http://www.di.uq.edu.au/sparqcbeifbackground) 
 
The advantage comparing with viral culture is that in antigen detection the 
non-viable viruses can be analyzed, which may be important when samples 
need a long transportation to the laboratory, but is not as sensible as the 
genome analysis. 
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• Rapid antigen test 
Rapid point-of-care tests can be done in 15 – 30 minutes and were designed 
for use where a preliminary screening test result is required, so, therefore 
can be performed in a doctor’s office, in an outpatient clinic or a hospital 
ward. These so called “point-of-care” tests have been in clinical use for over 
20 years for the detection of IV and RSV [72,73]. They have the advantage of 
being a rapid bed-side test. The diagnostic sensitivity and reliability of such 
rapid tests remains to be a topic of discussion. The main characteristics are 
that they are quick and easy to perform and require little or no additional 
equipment, but in the other hand, they are lack in sensitivity compared to 
virus isolation and genome detection. 
Polymerase Chain Reaction 
Kary Mullis and cols developed the polymerase chain reaction (PCR) 
technique in 1986 [71]. It is an enzymatic DNA amplification process divided 
in series of cycles based in the DNA replication. Ideally, every cycle of the 
PCR process doubles the amount of the desired DNA fragment available, 
resulting in exponential product accumulation. The new molecules 
synthesized (amplicons) can be visualized by fluorescence. 
In brief the PCR process includes the following steps: 
1. Extraction of genetic material from the sample. 
2. Transformation of RNA to complimentary DNA (if the virus is an RNA 
virus), by the enzyme reverse transcriptase. 
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3. Repeated amplification cycles. 
Even though the PCR has been known for more than 25 years, it is not wide 
used in diagnosing viral respiratory infections. One reason is that more than 
one virus was detected in the same sample, and consequences of this co-
infection are not fully understood. 
• PCR phases: 
A PCR reaction can be divided into three distinct phases: exponential, linear, 
and plateau (Figure 15). 
1. Exponential phase: 
It is the first phase in a PCR reaction in which, considering a reaction with a 
100% of efficiency, in each cycle the amount of product is doubled. At the 
end of this phase, as the amplicon exponentially accumulates in quantity and 
the PCR components decreases, the primer starts competing with amplicon, 
and the reaction efficiency decreases.  
2. Linear phase: 
In this phase, the reaction reduces the quantity of amplicon, so there is no 
longer near doubling of the amplicon. The product formed is highly variable 
due to many factors, including differences in the rate at which specific 
components are depleted and the accumulation of products. 
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3. Plateau phase: 
Finally the reaction will slow down and stop due to depletion of substrates 
and product inhibition. Each replicate reaction can plateau at different points 
due to different reaction kinetics unique to each sample.  
 
Figure 15: Example plot of an experimental PCR reaction. 
x axis: cycle number; y axis: amount of DNA (RFU: relative fluorescence units). Colors represent 
number of input DNA molecules. (http://www.5prime.com) 
• Types of PCR 
Since its development, the original method has experienced different 
modifications or adaptations. 
1) Real time PCR 
It is a modification to PCR first introduced in 1992 by Higuchi et al. and it has 
realized a rapid increase in its use since then. 
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Real-time PCR is a sensitive and reliable method for detection of nucleic 
acids (DNA and RNA-cDNA) levels. It is based on detection of fluorescence 
emitted from a reporter molecule and this signal increases in direct 
proportion to the amount of PCR product in a reaction. By recording the 
amount of fluorescence emission at each cycle, it is possible to monitor the 
PCR reaction during exponential phase where the first significant increase in 
the amount of PCR product correlates to the initial amount of target template. 
How quickly the amplified target reaches a threshold detection level 
correlates with the amount of starting material present. A significant increase 
in fluorescence above the baseline value measured during the 3-15 cycles 
indicates the detection of accumulated PCR product. 
a) Quantitative PCR 
Real-time qPCR is based on detection and quantification of fluorescence 
emitted from a reporter molecule at real time. This detection occurs during 
the accumulation of the PCR product with each cycle of amplification, thus 
allows monitoring the PCR reaction during early and exponential phase 
where the first significant increase in the amount of PCR product correlates 
to the initial amount of target template. 
2) Nested PCR 
Nested polymerase chain reaction is a modification of PCR aimed to reduce 
non-specific binding or contamination in products due to the amplification of 
unexpected or unintended primer binding sites (mispriming). Conventional 
PCR requires primers complementary to the termini of the DNA target but 
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primers could bind to incorrect regions of the DNA, giving unexpected 
products. Nested PCR can increase the yield and specificity of amplification 
of the target DNA. Nested PCR involves two sets of primers in two 
successive rounds of PCR. This involves taking an aliquot of the product 
from the primary PCR, and using it as a template for a secondary round of 
PCR amplification: 
• The first primer set binds to sequences outside the target DNA, as 
expected in standard PCR. In this first step fewer nonspecific 
amplification products are produced. 
• The second set of primers will bind and amplify target DNA within the 
products of the first reaction. 
3) Reverse transcription PCR 
In RT-PCR, the RNA template is first converted into a complementary DNA 
(cDNA) using a reverse transcriptase. The cDNA is then used as a template 
for exponential amplification using PCR. RT-PCR is currently the most 
sensitive method of RNA detection available. The use of RT-PCR for the 
detection of RNA transcript has revolutionalized the study of gene expression 
in the following important ways: 
• Made it theoretically possible to detect the transcripts of practically 
any gene. 
• Enabled sample amplification and eliminated the need for abundant 
starting material that one faces when using northern blot analysis. 
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• Provided tolerance for RNA degradation as long as the RNA spanning 
the primer is intact. 
4) Multiplex PCR  
Multiplex PCR refers to a process whereby several agents can be analyzed 
in the same test run, by using multiple primer sets within a single PCR 
mixture. Amplicons (amplification products sized ≈ 80-150 bp) of varying 
sizes, specific to different DNA sequences, are produced. Even though 20 or 
more different pathogens are analyzed simultaneously. Multiplex PCR uses 
multiple pairs of primers in the same reaction to amplify multiple sequences 
of DNA. This allows the detection and identification of multiple viruses within 
one reaction.  
1.5 Co-infection and superinfection 
Co-infection and superinfection describe both a secondary infection of a 
previously infected patient. The time when the second infection occurs is the 
main difference between the two concepts (Figure 16).  
Co-infection is the simultaneous infection of a host by multiple pathogens, 
that is infection occur at the same time. Global prevalence of co-infection is 
unknown, but it is thought to be usual and more common than single 
infection in respiratory illness. 
In the other hand, superinfection is defined as a new infection occurring in a 
patient having a pre-existing infection, such as bacterial superinfection in 
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viral respiratory disease. The second infection superimposed is resistant to 
the treatment used against the first infection.  
 
Figure 16: Differences between co-infection and superinfection. 
 
Co-infection and superinfection are important concepts on human health 
because different pathogen species can interact within the host and the 
resulting effect is not clear in all the cases, but some of the interactions are 
thought to have negative effects. 
The importance of co-infections in respiratory infections 
The arrival of molecular methods in the biomedical sciences has given 
investigators the ability to detect co-infections with increasing facility. 
However, little is known about the clinical significance of these multiple 
infections compared to single pathogen infections.  
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• Viral co-infection 
There is controversy in the importance and impact of viral co-infection in 
respiratory diseases. The elucidation of the epidemiologic and clinical 
importance of mixed respiratory infections has become an area of active 
research in recent years. Co-infection rates vary widely among these studies 
and are estimated to account for 47% and 95% [7,74,75] of ARI for which at 
least one virus was detected in children. 
• Virus-bacteria disease 
Co-infections could be acute and chronic infections caused by various 
combinations of viruses, bacteria, fungi, and parasites [76]. It is set that for 
virus-bacteria infection, for example, the infection arise when the virus 
creates a niche for or predisposes the host to colonization by other 
pathogens (bacteria). The majority of deaths in the 1918-1919 influenza 
pandemic likely resulted from secondary bacterial pneumonia [77]. Many 
factors are involved in the phenomenon of bacterial superinfection during 
viral respiratory disease as it is represented in Figure 17. Virus could 
predispose bacterial infection in respiratory tract by different mechanisms 
[78]: 
• Physical damage to the local respiratory physical barriers: Viruses 
may render the epithelium more susceptible to bacterial colonization 
by altering the mucosal surfaces. Cilia may be damaged, leading to 
decreased mucociliar function of the respiratory epithelium. 
Additionally, due to viral-induced damage and loss of integrity of the 
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epithelium layer, bacterial colonization may be enhanced and 
translocation may be increased.  
• Virus-infected cells may decrease the expression of antimicrobial 
peptides, as shown for b-defensins, thereby affecting the natural 
defense of the host epithelium.  
• Viral neuraminidase activity is able to cleave sialic acids residues, 
thereby giving access to bacterial receptors that were covered by 
these residues. 
• Viruses may induce bacterial colonization and replication both directly 
and indirectly, the latter by inducing up-regulation of various receptors 
required for bacterial adherence. 
 
Figure 17. Mechanism of the viral–bacterial interaction on the respiratory epithelial surface. Viral 
presence is thought to predispose the respiratory niche to bacterial colonization by different 
mechanisms [78]. 
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2 BACKGROUND & 
OBJECTIVES 
Viral co-infections in the nasopharynx 
While the clinical features of ARIs are easily recognized, the etiological agent 
responsible for disease is often not detected with non-molecular diagnostic 
techniques, which typically use direct immunofluorescence to detect RSV, IV, 
hPIV and AdV. In this regard, the etiology of most lower respiratory tract 
infection is thought to be viral, but a virus is identified in approximately 40% 
of cases with this approach [10]. Molecular techniques, including PCR, 
increase the sensitivity of detection for common and emerging respiratory 
viruses [79], and often reveal the presence of more than one pathogen. 
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Laboratory diagnosis and surveillance of respiratory infections are important 
due to rapid identification of the causing agent can help to take decisions 
concerning optimal antimicrobial or symptomatic treatment strategies. Also, 
the recognition of the causative agent may help prevent further spread of the 
pathogen by reducing social contacts. The importance of co-infections in the 
pathogenesis, severity or course of respiratory infections is not well 
established. 
Viral-bacterial interaction 
The main complication of viral respiratory infections is bacterial co-infection 
and the synergism established between viral and bacterial infections, which 
have been widely discussed in the literature, particularly for respiratory 
viruses and secondary bacterial pneumonia [64]. Bacterial superinfection is 
the most important and frequent complication in infants and children with viral 
ARI. In the setting of acute bronchiolitis, the risk of bacterial infection is low in 
children with respiratory illness [65-68]. However, these studies focused on 
fever as a predictive value of bacterial infections diagnosed by culture. 
Objectives 
With this background, the overall purposes of the current study were: 
i) To assess the epidemiology of viral co-infection in hospitalized 
children with ARI using molecular diagnosis and to evaluate its 
eventual influence in the clinical phenotype and disease course. 
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ii) To determine the actual rate of bacteraemia assessed by molecular 
techniques in children admitted to hospital due to confirmed RSV 
acute respiratory illness. 
The specific aims were: 
• To examine the rate and pattern of viral co-infection in children with 
lower respiratory tract infections using a multiplex PCR assay. 
• To analyze the impact of the viral pattern on the clinical presentation 
and the duration of symptoms in children with lower respiratory tract 
infections in an inpatient setting. 
• To investigate if patient’s age could affect the viral pattern and clinical 
significance. 
• To describe the seasonal distribution of respiratory pathogens as 
detected using multiplex PCR in children hospitalized with ARI. 
• To investigate the actual rate of bacteremia in RSV infected infants 
using molecular methods and its impact on the clinical phenotype and 
antibiotic prescription rates. 
 

	  
3 
3 MATERIAL & 
METHODS 
3.1 Study design and recruitment criteria 
Viral co-infection 
Two independent observational, prospective patient groups were collected in 
Spain (main group) and in the United Kingdom (replication group). Spanish 
children were recruited between January 2011 and January 2013 through a 
national hospital based research network: GENDRES (Genetic, vitamin D 
and Respiratory infections research network – www.gendres.org), which 
includes 13 Spanish tertiary hospitals (Figure 18). UK children were recruited 
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between October 2009 and May 2010 at St Mary’s hospital (UK). In both 
cohorts, eligible study participants were previously healthy children under 14 
years of age with respiratory illness of sufficient severity to warrant admission 
to hospital.  
 
Figure 18: GENDRES network. Participant hospitals are shown. 
	  
Viral-bacterial interaction 
Previously healthy infants admitted to any of the participant hospitals in 
GENDRES network with confirmed RSV infection were included. Positive 
RSV results for perform the blood PCR was considered when in both 
immunofluorescence (hospital) and PCR techniques the virus was detected. 
 
Hospital Virgen de la Arrixaca, Murcia 
Hospital Carlos Haya, Málaga 
Hospital Quirón, Málaga 
Complejo Hospitalario de Jaén 
Hospital Materno Infantil Virgen del Camino de 
Pamplona: 
Complejo Hospitalario Universitario de Orense 
Hospital Torrecárdenas, Almería: 
Hospital Severo Ochoa de Madrid 
Hospital de León 
Hospital de Donostia, San Sebastián: 
Complejo Hospitalario Universitario de Santiago de Compostela 
Complejo Hospitalario de Pontevedra 
Hospital Sant Joan de Déu 
GENVIP (www.genvip.org) 
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3.2 Ethical clearance 
All investigators were trained in the study protocol for patient recruitment, 
sample processing and sample storage. The study was performed according 
to Good Clinical Practice. Written informed consent was obtained from a 
parent or legal guardian for each subject before study inclusion (Appendix 
Figure 1). The study was approved by the Ethical Committee of Clinical 
Investigation of Galicia (CEIC ref. 2010/015). The UK cohort study was 
approved by the St Mary’s Research Ethics Committee (REC 09/H0712/58).  
 
3.3 Laboratory methods 
During hospitalization a nasopharyngeal sample was obtained using a sterile 
feeding tube and injector for nasopharyngeal aspirate/wash or a sterile nylon 
swab (FLOQSwabsTM by Copan Diagnostics, Brescia, Italy) without culture 
medium.  
The swab was inserted into one nostril straight back (not upwards) to the 
nasopharynx and was leaved in place for 2-3 seconds with small rotating 
motion to absorb secretions. Finally the swab was slowly removed (Figure 
19). 
For the nasopharyngeal aspirate a Mucus extractor (Poly medicure limited, 
Brussels, Belgium) was used. The coned section was placed in the infant's 
nasopharynx area. Suction was applied via the green cone end using either a 
pump system or manual suction to retrieve mucus sample (Figure 19). When 
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sufficient sample was obtained, the cap and tube assembly was removed 
and replaced with spare container cap supplied. 
 
Figure 19: Collection methods of the nasopharyngeal samples in the study. Swab and nasopharyngeal 
aspirate collection is shown. 
 
A blood sample was also collected by venipuncture from each patient at the 
same time point for analysis BD Vacutainer® K2E 5.4mg tube (Becton 
Dickinson, Franklin Lakes, Plymouth, UK). Samples were stored at 4ºC for up 
to 24 hours before being stored at -80ºC. Samples were transported on dry 
ice to the Micropathology Laboratory (Coventry, United Kingdom) for viral 
and bacterial nucleic acid amplification. This PCR was an additional 
determination to the diagnostic work-up performed at physician discretion at 
the hospital of origin, which usually included direct immunofluorescent 
assays to detect influenza A and B, RSV, metapneumovirus, parainfluenza 
and adenovirus. 
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Viral PCR in nasopharyngeal samples 
A panel of 19 viruses was investigated in nasopharyngeal samples by real 
time nested PCR: 
• Respiratory syncytial virus 
• Influenza (A, B) 
• Parainfluenza types (1-4) 
• Adenovirus (A-F) 
• Rhinovirus 
• Metapneumovirus 
• Coronavirus (NL63, 229E, OC43) 
• Bocavirus 
The real-time PCR procedure used in the study is based on automated 
specimen extraction and multiplex amplification. Nasopharyngeal samples 
were tested in Micropathology lab. Nucleic acid extracts were prepared from 
200 µl sample using a QiagenMDx BioRobot. In the RNA virus (RSV, hRV, 
hPIV, Flu, hCoV, hMPV) a reverse transcription process was made in which 
a single-stranded genomic RNA was converted into double-stranded cDNA. 
First round amplification was performed using 20 µl nucleic acid extract. 
Second round PCR was performed using 1 µl amplicon from first round PCR 
as template material. Reactions were run using a Lightcycler®480 with melt 
curve analysis for the detection of PCR products. The LightCycler®480 
System is a high-performance, flexible throughput PCR platform from Roche 
Diagnostics. 
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Second round PCR products of AdV were analyzed using standard Sanger 
sequencing procedures. An ABI 3130xl genetic analyzer (Applied 
Biosystems®) in combination with ABI BigDye 3.1 technology to perform an 
in-house sequencing was used. The BigDye Terminator v3.1 Cycle 
Sequencing Kit provides the required reagent components for the 
sequencing reaction in a ready reaction, pre-mixed format. Sequences were 
analyzed using the BLAST algorithm. 
Virus Gene targets 
Influenza A [80] Gene N 
Influenza B [81] Gene M 
Metapneumovirus [82] Gene N 
RSV [83] Gene N 
Parainfluenza 1 [80] Gene HN 
Parainfluenza 2 [84] Gene HN 
Parainfluenza 3 [84] Gene HN 
Parainfluenza 4 [85] Gene P 
Rhinovirus [86] 5’ UTR 
Adenovirus (A-F) [87,88] Hexon 
Bocavirus [89] NS encoding region 
Coronavirus NL63 [90] Gene N 
Coronavirus 229E [91] Gene M 
Coronavirus OC43 [92] Gene N 
 
Table 5. PCR gene targets and sources from which the primers were obtained. 
 
• Sequencing: Sanger method 
DNA sequencing is the process of determining the precise order of 
nucleotides within a DNA molecule. Fred Sanger developed the first method 
of sequencing the genetic code in 1977. Before the DNA can be sequenced, 
it has to be denatured into single strands using heat. A sequencing reaction 
mix containing amplified template DNA, oligonucleotide primers and a 
mixture of dNTPs and fluorescently tagged terminator dNTPs is heated to 
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95oC to denature the double stranded DNA template. The primers are 
specifically constructed so that its 3' end is located next to the DNA 
sequence of interest. 
The temperature is reduced and short, complementary primers bind to the 
now single-stranded template. A subsequent extension step at an enzyme-
specific temperature allows DNA polymerase to replicate the template. The 
inclusion of chain-terminating fluorescently tagged nucleotide analogues 
leads to the random termination of growing DNA molecules. 
Next a primer is annealed to the single stranded DNA. This primer is 
specifically constructed so that its 3' end is located next to the DNA 
sequence of interest. Then reagents are added to the primer and template, 
including: DNA polymerase, dNTPs, and a small amount of all four 
dideoxynucleotides (ddNTPs) labeled with fluorophores. During primer 
elongation, the random insertion of a ddNTP instead of a dNTP terminates 
synthesis of the chain because DNA polymerase cannot react with the 
missing hydroxyl. This produces all possible lengths of chains. Then the 
products are separated on a single lane capillary gel, where the resulting 
bands are read by an imaging system. 
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Figure 20: DNA sequencing. (www.the-scientist.com) 
	  
• Blast algorithm 
We used the Basic Local Alignment Search Tool (BLAST), which is one of 
the most widely used bioinformatics programs for sequence searching. It is 
an algorithm for comparing primary biological sequence information as the 
nucleotides of DNA sequences. A BLAST search enables a researcher to 
compare a query sequence with a library or database of sequences, and 
identify library sequences that resemble the query sequence above a certain 
threshold. The BLAST finds regions of local similarity between sequences. 
The program compares nucleotide to sequence databases and calculates the 
statistical significance of matches. BLAST can be used to infer functional and 
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evolutionary relationships between sequences as well as help identify 
members of gene families. 
Bacterial PCR in blood samples 
In the positive RSV samples, an eight bacteria PCR was performed in blood, 
searching for:  
• Meningococcus 
• Streptococcus pneumonia 
• Haemophilus influenza 
• Streptococcus pyogenes 
• Klebsiella pneumonia 
• Pseudomonas aeruginosa 
• Escherichia coli 
• Staphylococcus aureus 
In the same way as for virus detection, for bacterial identification a real-time 
PCR procedure was used based on automated specimen extraction and 
multiplex amplification. Blood samples collected in the same timepoint than 
the nasopharyngeal samples were tested in Micropathology lab. Nucleic acid 
extracts were prepared from 200 µl sample using a QiagenMDx BioRobot. 
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3.4 Clinical data collection 
Detailed clinical data on each patient were collected using a secured web-
based platform (www.gendres.org) 
 
Figure 21: GENDRES secure web page is presented (www.gendres.org). 
 
This included risk factors for ARI (ethnicity, prematurity, immunization status, 
obesity, diabetes, asthma and previous admissions to hospital), current 
medications, and family history of asthma or other respiratory conditions. 
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Severity of the episode 
Clinical information of the episode of the illness during admission was 
documented (Appendix Figure 2). A specific questionnaire had to be 
answered and recorded searching information as hospital stay of length, if 
the patient was admitted to PICU, treatments during hospitalization or 
discharge diagnosis. Supplemental oxygen and / or mechanical ventilation 
requirement during admission were also recorded. Respiratory support was 
considered as either invasive (mechanical ventilation) or non-invasive 
ventilation (CPAP, BiPAP). The few patients using Optiflow® were included 
under the non-invasive ventilation category, although this could be debatable 
as the inadvertent PEEP generated by this technology cannot be strictly 
considered a non-invasive mode. The referring physician, with reference to 
clinical data, inflammatory markers, radiological findings and/or appropriate 
cultures, assessed the possibility of bacterial co-infection  
The severity of each respiratory episode was ranked as follows:  
1. Physician criteria (mild, moderate or severe). The respiratory distress 
was rated in the worst moment of the illness. 
2. Modified Wood-Downes scale (0 to 10 points; mild <3, moderate 4 - 7, 
severe >8).  In children with bronchiolitis and asthma,r severity 
assessment can be performed using the Wood-Downes scale which 
analyzes the following variables: 
 
3. Material	  and	  methods	  
60 
 0 0.5 1 2 
Oxygenation 
SatO2 
≥95% 
ambient 
95%>SatO2≥90% 
ambient 
SatO2 ≥90% with 
FiO2 >21 
SatO2 
<90% with 
FiO2 >21 
Inspiratory 
breath 
sounds 
Normal Discreetly unequal Highly unequal Decreased or absent 
Expiratory 
wheezing None Mild Moderate Maximal 
Accessory 
muscles None Mild Moderate Marked 
Cerebral 
function Normal 
Agitated when 
stimulated Depressed/agitated Coma 
 
Table 6. Modified Wood-Downes Score. 
 
3. A newly developed scale -named GENVIP score- (0 to 20 points) that 
assesses food tolerance, degree of medical intervention needed, 
respiratory distress, respiratory frequency, apnea, malaise and fever. 
For each of the 6 items, the clinician had to choose the option that 
better described the situation of the child. The worst condition anytime 
during the whole course of the patient illness was considered. 
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0 
points 1 points 2 points 3 points 
1 Feeding intolerance 
No Mild Decreased appetite 
and/or isolated vomits 
with cough. 
Partial 
Frequent vomits with 
cough, rejected feed but 
able to tolerate fluids 
sufficiently to ensure 
hydration 
Total 
Oral intolerance or 
absolute rejection of oral 
feed, not able to guarantee 
adequate hydration orally. 
Required nasogastric 
and/or intravenous fluids 
2 Medical intervention 
No Basic Nasal secretions 
aspiration, physical 
examination, trial of 
nebulised bronchodilators, 
antipyretics. 
Intermediate 
Oxygen therapy required. 
Complementary exams 
were needed (chest X-ray, 
blood gases, 
hematimetry…). 
Maintained nebulised 
therapy with 
bronchodilators 
High 
Required respiratory 
support with positive 
pressure (either non-
invasive in CPAP, BiPAP 
or high-flow O2; or 
invasive through 
endotracheal tube). 
3 Respiratory difficulty 
No Mild Not in basal situation but 
do not impress of severity. 
Wheezing only audible 
with stethoscope, good air 
entrance. If modified 
Wood Downes, Wang 
score or any other 
respiratory distress score 
is applied, punctuation 
reveals mild severity. 
Moderate 
Makes some extra 
respiratory effort 
(intercostal and/or 
tracheosternal retraction). 
Presented expiratory 
wheezing audible even 
without stethoscope, and 
air entrance may be 
localized decreased. If 
modified Wood Downes, 
Wang score or any other 
respiratory distress score 
is applied, punctuation 
reveals mild severity. 
Severe 
Respiratory effort is 
obvious. Inspiratory and 
expiratory wheezing and/or 
clearly decreased air entry. 
If modified Wood Downes, 
Wang score or any other 
respiratory distress score 
is applied, punctuation 
reveals mild severity. 
4 Respiratory frequency 
Normal Mild/occasional tachypnea 
Presented episodes of 
tachypnea, well tolerated, 
limited in time by self-
resolution or response to 
secretion aspiration or 
nebulisation. 
Prolongued/ 
recurrent tachypnea 
Tachypnea persisted or 
recurred despite secretion 
aspiration and/or 
nebulisation with 
bronchodilators. 
Severe alteration 
Severe and maintained 
tachypnea. Very superficial 
and quick breath rate. 
Normal/low breath rate 
with obvious increased 
respiratory effort and/or 
mental status affected. 
Orientative rates of severe 
tachypnea: 
< 2 m: > 70 bpm 
2-6 m: > 60 bpm 
6-12m: >55 bpm 
12-24m: >50 bpm 
24-36m: >40 bpm 
5 Apnea 
No   Yes At least one episode of 
respiratory pause 
medically documented or 
strongly suggested 
through anamnesis. 
6 General Condition 
Normal Mild Not in basal situation, 
child was mildly 
uncomfortable but did not 
impress of severity. 
Parent are not alarmed. 
Could wait in the waiting 
room or even stay at 
home. 
Moderate 
Patient looks ill, and will 
need medical exam and 
eventually further 
complementary exams 
and/or therapy. Parent are 
concern. Not to be waiting 
in the waiting room. 
Severe 
Agitated, apathetic, 
lethargic. No need to be 
physician to be worried. 
Parent are very concern. 
Immediate medical 
evaluation and/or 
intervention was required 
7 Fever No 
Yes, mild 
Central Tª <38,5ºC 
Yes, moderate 
Central Tª 38,5-39C 
Yes, severe 
Central >39ºC 
 
Table 7. GENVIP Score. Clinical severity score for healthy infants with respiratory infections 
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3.5 Data analysis 
In the data analysis, we compared clinical data to the results of pathogen 
identification in respiratory and blood samples. General data are shown as 
percentages or means with 95% confidence intervals (CI). The level of 
statistical significance was set to 0.05. Statistical tests and Figures were 
carried out using R software v. 3.0.2 (R Core Team (2013). R: A language 
and environment for statistical computing. R Foundation for Statistical 
Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-
project.org/http://www.r-project.org). 
Different statistical models were used to assess the bivariate association 
between the variables depending on the dependent variable.  
Odds ratio calculation 
An odds ratio (OR) is a measure of association between an exposure and an 
outcome. The OR represents the odds that an outcome will occur given a 
particular exposure, compared to the odds of the outcome occurring in the 
absence of that exposure. 
𝑂𝑅 =
𝑎  ×  𝑑
𝑏  ×  𝑐  
𝑂𝑅× exp   (±  1,96  ×  
1
𝑎   +   
1
𝑏   +   
1
𝑐   +   
1
𝑑) 
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The odds ratio is always a positive value, and can also be used to determine 
whether a particular exposure is a risk factor for a particular outcome, and to 
compare the magnitude of various risk factors for that outcome. 
• OR = 1 Exposure does not affect odds of outcome 
• OR > 1 Exposure associated with higher odds of outcome 
• OR < 1 Exposure associated with lower odds of outcome 
The 95% CI is used to estimate the precision of the OR. A large CI indicates 
a low level of precision of the OR, whereas a small CI indicates a higher 
precision of the OR. 
Simple regression models 
The logistic regression models are statistical models in which you want to 
know the relationship between a dichotomous qualitative dependent variable 
(binary logistic regression) or with more than two values (multinomial logistic 
regression) and one or more independent explanatory variables (covariates), 
whether qualitative (dicotomic) or quantitative. In simple linear regression, we 
predict scores on one variable from the scores on a second variable. Simple 
linear regression fits a straight line through the set of n points in such a way 
that makes the sum of squared residuals of the model (that is, vertical 
distances between the points of the data set and the fitted line) as small as 
possible. 
Depending on the characteristics of the variables (binary, continuous, etc) 
the simple regression models can be categorized in: 
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• Binary logistic model 
• Linear model 
• Multinomial logistic model. 
Multiple regression models 
Multiple regression is an extension of simple linear regression. Regression 
analysis is a statistical process for estimating the relationships among 
variables. It includes many techniques for modelling and analysing several 
variables, when the focus is on the relationship between a dependent 
variable and one or more independent variables. It is used when we want to 
predict the value of a variable based on the value of two or more other 
variables. The variable we want to predict is called the dependent variable 
(or sometimes, the outcome, target or criterion variable). The variables we 
are using to predict the value of the dependent variable are called the 
independent variables (or sometimes, the predictor, explanatory or regressor 
variables).  
X2 test 
A chi square (X2) statistic is used to investigate whether distributions of 
categorical variables differ from one another. 
2 x 2 Contingency Table: There are several types of chi square tests 
depending on the way the data was collected and the hypothesis being 
tested. The simplest case is a 2 x 2 contingency table. If we set the 2 x 2 
table to the general notation shown below in Table 1, using the letters a, b, c, 
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and d to denote the contents of the cells, then we would have the following 
table: 
Variable 2 Data type 1 Data type 2 Totals 
Category 1 a b a + b 
Category 2 c d c + d 
Total a + c b + d a + b + c + d = N 
 
Table 8. General notation for a 2 x 2 contingency table for Variable 1. 
 
Fisher’s exact test 
It is a statistical significance test used in the analysis of contingency tables. 
The test is useful for categorical data that result from classifying objects in 
two different ways; it is used to examine the significance of the association 
(contingency) between the two kinds of classification. 
Wilcoxon test 
The Wilcoxon test is a non-parametric statistical hypothesis test used when 
comparing two related samples, matched samples, or repeated 
measurements on a single sample to assess whether their population mean 
ranks differ. 
Bonferroni correction 
The Bonferroni correction is an adjustment made to P values when several 
dependent or independent statistical tests are being performed 
simultaneously on a single data set. To perform a Bonferroni correction, a 
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division of the critical P value (α) by the number of comparisons being made. 
For example, if 10 hypotheses are being tested, the new critical P value 
would be α/10. The statistical power of the study is then calculated based on 
this modified P value. 
The Bonferroni correction is used to reduce the chances of obtaining false-
positive results (type I errors) when multiple pair wise tests are performed on 
a single set of data. 
False Discovery Rate 
The False discovery rate (FDR) is one way of conceptualizing the rate of type 
I errors in null hypothesis testing when conducting multiple comparisons. 
FDR-controlling procedures are designed to control the expected proportion 
of rejected null hypotheses that were incorrect rejections. 
Data analysis applied in our study 
• The relationship between demographic and clinical variables with mono-
infection and co-infection was analyzed using simple logistic regression. A 
binary logistic model was used for the binary variables (co-infection status, 
oxygen requirements, respiratory support needed and PICU admission), 
linear model for continuous variables (Wood-Downes Score and GENVIP 
Score), negative binomial regression model for counted data (hospital stay 
length) and logistic multinomial model for the multinomial variable 
(respiratory distress status).  
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• Multiple regression models were considered using the significant risk 
factors obtained in the bivariate analysis and sex and age variables. In 
order to reduce the likelihood of false significant results due to too many 
statistical comparisons, the Bonferroni multiple test correction and False 
Discovery Rate were considered.  
• A χ2 test was performed to evaluate the correlation between bacterial 
superinfection and pneumococcal vaccine.  
• For viral-bacterial interaction the Fisher’s exact test for discrete variables 
and Wilcoxon test for continuous variables were used. 
• Fisher’s exact test was used to study the association between the viruses 
and PICU admission.   
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4 RESULTS 
4.1 General characteristics of the GENDRES 
and UK cohort 
The GENDRES cohort had a median age of 6.4 (first quartile: 2.2, third 
quartile: 17.0) months and a male-to-female sex ratio of 1.7. One patient was 
excluded due to incomplete clinical data (Figure 22). The cohort included 
nasopharyngeal samples from 204 patients: 23 (11.3%) nasopharyngeal 
swabs and 181 (88.7%) nasopharyngeal aspirates/wash. No differences in 
findings were observed in relation to the method used for sample collection 
(data not shown). 
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The UK cohort included samples from 97 patients, with a median age of 20.0 
(first quartile: 7.0, third quartile: 48.7) months and a male-to-female ratio of 
0.94. (Figure 22).  
 
 
Figure 22: Flow chart of study population of the main cohort (GENDRES cohort) and replication cohort 
(UK cohort) 
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Comparison between both cohorts is shown in Table 9. 
 
Table 9. Description of the characteristics of the two cohorts analyzed: the GENDRES cohort and the 
UK cohort. 
P-value results from the comparison between both cohorts. A P-value < 0.005 was considered 
significant. (1) Fisher Exact Test. (2) Wilcoxon test. (*) Mean and Standard deviation in days. (β) 
Significant under Bonferroni correction. 
 
4.2 Molecular diagnostics 
Molecular diagnostics in the GENDRES cohort 
Molecular diagnostics identified at least one pathogen in 187 samples. Of 
these PCR positive samples, 73 had previously yielded negative results 
using conventional methodology – immunufluorescence assays and/or rapid 
techniques. Five samples (2.5%) were negative for both PCR and the initial 
diagnostic work-up. In 12 cases (5.9%) where the referring hospital had 
established a diagnosis, PCR was negative (RSV, n = 8; IV H1N1, n = 2; 
Mycoplasma, n = 1; and Influenza C, n = 1). By PCR multiplex assay, a 
Variable GENDRES cohort n (%) 
UK cohort 
n (%) P-value 
Sex (female proportion) 1 75 (36.9) 50 (51.5) 0.018 
Age (months) 1   <0.001β 
0-12 136 (66.7) 39 (40.2)  
13-24 25 (12.3) 17 (17.5)  
25-48 26 (12.8) 17 (17.5)  
<48 16 (7.9) 24 (24.7)  
Pneumoccocal vaccine1 110 (53.9) 57 (64.0) 0.124 
Bacterial superinfection1 56 (29.5) 53 (54.6) <0.001β 
PICU admission1 38 (29.0) 43 (44.3) 0.024 
Respiratory support1 30 (14.8) 36 (38.3) <0.001β 
Oxygen needed1 56 (29.5) 55 (57.9) <0.001β 
Hospital stay length2* 15.4 (8.8) 7.3 (9.1) <0.001β 
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single pathogen was detected in 95 (46.6%) children and two or more 
pathogens were detected in 92 (45.1%) patients, giving an overall detection 
rate of 91.7%. The most commonly detected virus was RSV (n = 108), 
followed by hRV (n = 68), hBoV (n = 48), AdV (n = 39), HMPV (n = 27), IV (n 
= 12), hPIV and hCoV (both n = 5) (Table 10). In co-infected samples, the 
most frequent combination of pathogens was RSV + hRV (n = 23) followed 
by RSV + hBoV (n = 10) and RSV + AdV (n = 7) (see Table 11). The virus 
most frequently found in dual infection was RSV (n = 42), followed by hRV (n 
= 35) (Table 10). RSV was observed with the same frequency as a single 
infection (n = 53) and as a co-infection agent (n = 55) (see Figure 23). 
However, hRV, IV, hBoV, AdV and hMPV were more frequently found in co-
infections (Figure 23).  
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Table 10. Distribution of viral agents according to age in the GENDRES cohort (GEN) and UK cohort 
(UK). Data are presented as number of positive samples (percentage of samples evaluated) or the 
mean (standard deviation). Age is expressed in months. 
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Figure 23. Pathogen prevalence in the main and replication cohorts showed as number in 
nasopharyngeal samples considering the age of the children. Only the more prevalent viruses are 
presented. 
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Table 11. Associations among respiratory pathogens in hospitalized children in the GENDRES cohort 
and UK cohort 
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Molecular diagnostics in the UK cohort 
We identified at least one virus in 85 (87.6%) samples; in 12 samples no 
virus was identified. A single virus was present in 56 (57.7%) patients, and 
two or more viruses in 29 (29.9%) children. The most commonly detected 
virus was RSV (n = 35), followed by hRV (n = 24), IV (n = 23), hBoV (n = 19), 
AdV (n = 9), HMPV (n = 4) and hPIV (n = 6) (Table 10). In the co-infected 
samples, the most frequent combinations were RSV + hBoV and IV + hBoV 
(both n = 5). The viruses most frequently found in dual infections were RSV 
and hBoV (both n = 12), followed by hRV (n = 9) and IV (n = 8) (Table 11). 
hRV and IV were observed with similar frequencies in single infection and co-
infection (hRV n = 11 vs 13; IV n = 13 vs 10), while hBoV and AdV were 
more frequently found as co-infections, and RSV was more commonly 
present as a single infection. 
Age differences in infection 
We compared co-infection frequencies according to age groups. In both 
cohorts, co-infection was found in all age groups. In the GENDRES cohort, 
there is a significant association between age and co-infection: in children 
aged 12 - 24 months (72.7% of infected patients; see Figure 23) and those 
aged 24 - 48 months (75.0% of infected patients; P-value = 0.001). In the UK 
cohort, there was also a significant association age and co-infection in 
patients aged 12 - 24 months (73.3% of the infected patients; P-value = 
0.005).  
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In the GENDRES cohort, RSV infection affected younger children more 
frequently (mean age: 8.1 months; SD: 14.9) and hPIV was principally found 
in older patients (mean age: 40.4 months; SD: 53.5) (Table 10). In the UK 
cohort, RSV infection also affected younger children more frequently (mean 
age: 12.8 months; SD: 14.6) and AdV predominated in older patients (mean 
age: 51.2 months; SD: 48.9). 
PICU admission differences in infection 
There was no significant difference in the number of infections between the 
PICU and non-PICU cohorts. Although modest differences were found for 
hBoV (PICU: 15.8% - non PICU: 22.6%) and hMPV (PICU: 2.6% - non PICU: 
14.0%) in the GENDRES cohort, these were not statistically significant. 
These differences were only observed in the UK cohort for hBoV (PICU: 
16.3% - non PICU: 22.2%) (Table 12). 
Virus 
GENDRES cohort UK cohort 
PICU (n=38) 
n (%) 
No PICU 
(n=93) 
n (%) 
P-value PICU (n=43) n (%) 
No PICU 
(n=54) 
n (%) 
P-value 
RSV 24 (63.2) 56 (60.2) 0.844 17 (39.5) 18 (33.3) 0.671 
hRV 15 (39.5) 28 (30.1) 0.312 11 (25.6) 13 (24.1) 1.000 
hBoV 6 (15.8) 21 (22.6) 0.479 7 (16.3) 12 (22.2) 0.451 
AdV 5 (13.2) 14 (15.1) 1.000 3 (7.0) 6 (11.1) 0.727 
hMPV 1 (2.6) 13 (14.0) 0.066 2 (4.7) 2 (3.7) 1.000 
IV 1 (2.6) 4 (4.3) 1.000 8 (18.6) 15 (27.8) 0.342 
hPIV 1 (2.6) 3 (3.2) 1.000 1 (2.3) 5 (9.3) 0.223 
hCoV 1 (2.6) 1 (1.1) 0.498 - - - 
 
Table 12. Virus detection in patients admitted to pediatric intensive care unit (PICU) in both cohorts. 
No differences were found when compared to those children not requiring PICU admission. 
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4.3 Severity of the illness 
Mono-infection versus Multi-infection 
Clinical data, family or past medical history, need of PICU admission or 
hospital length of stay, and oxygen or respiratory support need, were 
equivalent in the GENDRES and the UK cohort (Table 13). In the GENDRES 
cohort the presence of rhinovirus as co-pathogen was associated with a 
significantly increased Wood-Downes score by 1.289 points (95% CI: 0.387, 
2.192; P-value = 0.006). RSV infection was associated with increased 
oxygen requirements [OR (95% CI): 3.154 (1.302, 7.966); P-value = 0.012] 
(Appendix Table 5). These isolated findings were not replicated in the UK 
cohort (Appendix Table 6). 
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Table 13. Relationship between demographic and clinical variables with mono-infection and co-
infection is shown. The correlation was analyzed using simple logistic regression. Data are presented 
as OR (95% confidence interval) and P-value. βSignificant under Bonferroni correction; ♯significant 
under FDR correction. n.a. not applicable. 
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Bacterial superinfection 
Children presenting a bacterial superinfection had more severe respiratory 
distress [OR (95% CI): 4.356 (1.564, 12.128); P-value = 0.005] and a higher 
severity score [2.124 (95% CI: 0.864, 3.385); P-value = 0.001]. They were 
more likely to be admitted to PICU in the GENDRES cohort [OR (95% CI): 
2.851 (1.300, 6.252); P-value = 0.009] and the UK cohort [5.357 (2.081, 
15.085); P-value = 0.001]. Children with bacterial co-infection required 
significantly more respiratory support in both cohorts: discovery cohort [OR 
(95% CI): 6.368 (2.724, 14.886); P-value < 0.001] and replication cohort [OR 
(95% CI): 3.432 (1.402, 8.404); P-value = 0.007], and they had a longer 
hospital stay in both cohorts: 1.48 days (P-value = 0.025) longer stay in 
GENDRES cohort and 1.87 days (P-value = 0.005) in UK cohort, respectively 
(Figure 24; Appendix Tables 1 - 8). In addition, 34.0% of the patients with 
bacterial infection in the GENDRES cohort received the pneumococcal 
vaccine and 24.7% did not receive it (P-value = 0.213). 
Pneumococcal vaccine 
In the GENDRES cohort the pneumococcal vaccine was given to 53.9% 
(46.9, 61.1) of the patients of whom 43.8% (33.3, 54.2) were mono-infected 
and 62.7% (52.2, 73.1) were viral co-infected patients [OR (95% CI): 1.550 
(0.821, 2.932); P-value = 0.176]. Vaccinated patients had lower risk of being 
admitted to PICU in GENDRES cohort [OR (95% CI): 0.301 (0.116, 0.735); 
P-value = 0.011] and in the UK cohort [OR (95% CI): 0.208 (0.046, 0.776); P-
value = 0.027] and had less risk of respiratory support requirement in the 
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main cohort [OR (95% CI): 0.324 (0., 0.790); P-value = 0.016] and in the 
replication one [OR (95% CI): 0.267 (0.070, 0.901); P-value = 0.040]. In the 
Spanish cohort, patients who received the pneumococcal vaccine received 
less oxygen support [OR (95% CI): 0.328 (0.162, 0.639); P-value = 0.001], 
and had a lower clinical severity score [-1.499 (95% CI: -2.768, -0.231) 
points; P-value = 0.021] and a lower respiratory distress score [OR (95% CI): 
2.917 (1.078, 7.889); P-value = 0.035]. These findings were not replicated in 
the UK cohort (Figure 24; Appendix Tables 1 - 8). 
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Figure 24. Influence of bacterial superinfection, pneumococcal vaccine and the presence of viral co-
infection on disease severity of children with ARI, according to oxygen and respiratory support 
requirement, clinical scales, hospital stay length and PICU admission. 
Data are shown as OR (95% CI) for both main cohort and replication cohort. A binary logistic model 
was used for the binary variables (co-infection status, oxygen requirements, respiratory support 
needed and PICU admission), linear model for continuous variables (Wood-Downes Score and the 
GENVIP score) and negative binomial regression model for counted data (number of days since 
admission). 
4.4 Seasonal and geographical distribution 
A strong seasonal pattern was exhibited by most viruses, the majority of 
which were mainly detected in the cold seasons: 23 (11.4%) in autumn and 
122 (60.4%) in winter, compared to 56 (27.7%) in spring and only 1 (0.5%) in 
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summer. Seasonal distribution varied according to the virus (Figure 25). AdV 
and hMPV were typically detected at the end of the winter season and during 
spring, while hRV were detected from the end of autumn to spring with a 
constant frequency during this period (plateau). RSV was mostly identified 
during winter with an incidence peak in January. hBoV respiratory infections 
occurred mainly in December and January with another epidemic peak in 
March. IV showed a peak during winter and hPIV and hCoV were 
infrequently observed throughout the year.  
Viruses were not found with any geographical distribution. We detected IV in 
the centre and south regions but not in the north ones. 
 
Figure 25. Seasonal distribution of respiratory viral agents. Monthly distribution of respiratory samples 
analyzed in the study from 2011-2013. 
We can see the different patterns of the virus and in all of them, we can observe that in summer the 
prevalence had been reduced to the minimum number of samples in the years analyzed. 
 
4. Results	  
84 
4.5 Virus-bacteria interaction 
In 130 patients a nasopharyngeal sample PCR was performed, and of these, 
a total of 66 patients with a positive RSV by immunofluorescence technique 
in a nasopharyngeal sample/rapid test and confirmed by PCR were included 
in this study (Figure 26).  
 
Figure 26. Flow chart of study population of the GENDRES cohort for bacterial presence in blood 
analysis. 
 
Almost all of the children (92.4 %) were <12 months of age and the majority 
(66.7%) of the patients were boys. Although most of the patients were 
previously healthy children, 3.0% had diagnosed asthma and 4.8 % were 
premature. 23 of 66 (34.9%) of these patients had suspicion of bacterial 
superinfection according to the referring physician and in 5 of these 23 
patients (21.7%) the bacterial superinfections were confirmed by 
microbiological methods in the referring hospital. In n = 7 (10.6%) patients 
molecular assessment revealed bacterial presence in the blood (Table 14).  
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Risk factor Total cohort (n = 66) 
Negative 
PCR 
(n = 59) 
Positive 
PCR 
(n = 7) 
P-value 
Demographics     
Sex. Female1  33.3% (22/66) 35.6% (21/59) 14.3% (1/7) 0.409 
Age1     1.000 
< 12 92.4 (61/66) 91.5 (54/59) 100.0 (7/7)  
12 - 24 3.0% (2/66) 3.4% (2/59) 0.0% (0/7)  
24 - 48 4.5% (3/66) 5.1% (3/59) 0.0% (0/7)  
Family history     
Asthma1 30.3% (20/66) 71.2% (42/59) 57.1% (4/7) 0.425 
Respiratory conditions1 30.3% (20/66) 28.8% (17/59) 42.9% (3/7) 0.425 
Medical history     
Premature1 4.8% (3/63) 3.6% (2/56) 14.3% (1/7) 0.302 
Pneumococcal vaccine 48.5 (32/66) 52.5% (31/59) 14.3% (1/7) 0.106 
Clinical data     
Oxygen needed1 80.3% (53/66) 78.0% (46/59) 100.0% (7/7) 0.329 
Respiratory support1 27.3% (18/66) 18.6% (11/59) 100.0% (7/7) <0.001 
Diagnosis1    0.739 
Bronchiolitis 78.8% (52/66) 76.3% (45/59) 100.0% (7/7)  
Pneumonia 6.1% (4/66) 6.8% (4/59) 0.0% (0/7)  
Others 15.2% (10/66) 16.9% (10/59) 0.0% (0/7)  
Respiratory distress1    0.001 
Mild 22.7% (15/66) 25.4% (15/59) 0.0% (0/7)  
Moderate 53.0% (35/66) 57.6% (34/59) 14.3% (1/7)  
Severe 21.2% (14/66) 13.6% (8/59) 85.7% (6/7)  
PICU1 57.1% (28/49) 50.0% (21/42) 100.0% (7/7) 0.015 
Fever1    0.733 
Febricula (< 38º) 37.5% (18/48) 36.6% (15/41) 42.9% (3/7)  
Fever (> 38º) 50.0% (24/48) 48.8% (20/41) 57.1% (4/7)  
Wood Downes Score 
(mean-SD)2 5.2 (2.4) 4.8 (2.2) 8.7 (1.1) <0.001 
GENVIP scale 
(mean-SD)2 11.1 (4.1) 10.1 (3.6) 17.0 (1.0) <0.001 
Hospital stay of length 
(mean-SD)2 8.0 (4.8) 7.5 (4.7) 12.1 (4.3) 0.007 
Suspected bacterial 
superinfectión1 34.8% (23/66) 30.5% (18/59) 71.4% (5/7) 0.044 
Blood culture     
Done. Yes1 60.0% (27/45) 55.3% (21/38) 85.7% (6/7) 0.215 
Positive1 3.8% (1/26) 0.0% (0/21) 17.0% (1/6) 0.222 
Antibiotic treatment1 66.7% (30/45) 63.2% (24/38) 85.7% (6/7) 0.395 
 
Table 14. Summary of the characteristics of RSV cohort and comparison between those with positive 
and negative blood PCR for bacteria. 
General data is presented as percentage or means with 95% confidence intervals. Different statistical 
models were used to assess the association between the variables: Fisher’s exact test (1) for discrete 
variables and Wilcoxon test (2) for continuous variables. 
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The pathogen found were H. influenzae (n = 4), S. pneumoniae (n = 1) and 
both simltaneously (n = 2).  The cycle thresholds were <20 except for S. 
pneumoniae in the co-infection cases, in which the cycle threshold was >25. 
Only one of these cases this bacteria had also been identified by 
conventional cultures.  
In nasopharyngeal samples, more than one virus was detected in 35 out of 
66 (53.0%) patients by molecular techniques. In bacterial PCR positive 
patients, viral co-infection was observed in 5 out of 7 (71.4%) subjects (Table 
15). However, results of positive blood cultures performed at hospital and the 
later PCR were not in agreement. There was only one patient in whom a 
blood culture was performed at the referring hospital with a positive result (H. 
influenzae and S. aureus) and when the molecular technique was performed 
a similar result was obtained. (H. influenzae) (Table 15). 
Antibiotic administration in patients with suspected bacterial superinfection 
was recorded in 50.0% (n = 33) of the RSV-infected patients and in 3.3% (n 
= 1) of these patients a bacterial superinfection was confirmed by 
conventional blood cultures. 
There was no correlation between the patients suspected of superinfection 
and/or prescribed antibiotic by the referring physician, and those with positive 
blood PCR results (Cohen’s kappa coefficient bacterial superinfection-PCR = 
0.15). A total of 87.5% of the patients presented fever: > 38ºC in 50% of the 
included children (24 out of 48), and mild fever in 18 of them (37.5%). Fever 
frequency in children with bacteremia confirmed by PCR was similar to that 
in the rest of the cohort (P-value = 0.733). 
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Table 15. Description of RSV infected patients with positive blood bacterial PCR. Abbreviatures: NINV: 
non-invasive ventilation, INV: invasive ventilation 
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Severity of the illness 
There were significant differences in terms of illness severity between 
children with positive bacterial PCR and those with negative results: PICU 
admission (100% vs. 50%, P-value = 0.015) and respiratory support 
necessity (100% vs. 18.6%, P-value < 0.001). Patients with confirmed 
bacteremia had a more severe respiratory affection than those with no 
bacteria identified in blood (Table 14). Both the Wood-Downes score and the 
GENVIP scale indicated a worse value in the blood PCR positive patients 
(mean = 8.7 points and 17.0 points, respectively) than in the blood PCR 
negative patients (mean = 4.8 points and 10.1 points) (P-value < 0.001 for 
both). Hospitalization was longer for children with PCR-confirmed bacteremia 
(mean = 12.1 vs. 7.5 days, P-value = 0.007) (Figure 27). 
 
 
 
Figure 27. (continues). Severity parameters for the patients: Wood Downes score, GENVIP score, 
length of hospitalization, oxygen, respiratory support, respiratory distress and PICU admission 
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Figure 27. Severity parameters for the patients: Wood Downes score, GENVIP score, length of 
hospitalization, oxygen, respiratory support, respiratory distress and PICU admission. Patients are 
classified as: positive RSV in nasopharyngeal sample, positive RSV with confirmed bacteremia, and 
positive RSV and suspected bacterial superinfection. 
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5 DISCUSSION 
5.1 Molecular diagnostics 
Multiple viruses are detected in at least one third of children hospitalized with 
LT-ARI. This rate reaches two thirds for patients in their second year of age. 
With the introduction of molecular techniques, the detection of multiple co-
infecting viruses has become common [79], though the prevalence of each 
virus varies between studies. Our results show that viral co-infection is 
frequent, particularly in children above one year of age: children aged 12-24 
months had the highest number of detected viruses, which may reflect slower 
clearance (and perhaps increased pathogenicity) following primary infection 
by a virus, and an immature immune system [7,93]. We observed that co-
infection rates were lower in older children in both cohorts, despite this group 
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being prone to greater LT-ARI exposure through increased participation in 
shared childcare groups. This finding is inconsistent with two previous 
reports. In particular, Chorazy et al. [94] reported a non-significant increase 
in co-infection in children aged 6 - 12 months, and co-infection decreased 
after one year with increasing age. Peng et al. [95] reported that co-infection 
was more frequent in children between 3 - 6 years of age.  
At least one respiratory pathogen was detected in 91.7% of the enrolled 
patients in the Spanish cohort and 87.2% in the UK cohort. This finding is in 
the upper end of the reported range in children (between 47% and 95%) 
[7,74,75]. Possible explanations for the wide differences in detection rates 
found in the literature include: (i) heterogeneity in studied populations 
(including genetic variability and predisposition), (ii) differences in respiratory 
symptoms at presentation (upper or lower respiratory symptoms), (iii) 
differences in the time of sampling, (iv) number of respiratory pathogens 
tested, and (v) the kind of diagnostic tests used [7,74,93]. Many patients had 
multiple respiratory viruses: 45.1% in the GENDRES cohort, and 29.9% in 
the UK cohort, which is again in the upper end of the reported range (17 - 
41%) [7,96,97].  
In 12 cases there was discordance between a negative PCR and a positive 
diagnostic pretest. This could be due to the different time of sampling, and/or 
it might be due to false positives, which are known to occur more frequently 
in rapid tests. We also found five negative samples (2.5%) for both PCR and 
pretest tested pathogens. These differences might be explained by the time 
and mode of collection of the samples. In some patients, the initial 
conventional viral test was performed on hospital admission samples, whilst 
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PCR was performed using samples obtained after the patients were 
transferred to PICU and recruited for the study. 
Some viruses were mainly present as co-infecting agents (hRV, IV, hBoV, 
AdV and hMPV) and rarely found as single pathogens. As previously 
reported [7,98,99], RSV was the most frequent pathogen in both cohorts, 
especially in younger children. The second virus most frequently detected by 
PCR was hRV. The clinical significance of a positive hRV PCR assay has 
been questioned, given that hRV has been detected in asymptomatic 
children even two weeks after the clinical symptoms had disappeared 
[100,101]. However, hRV has been identified as single pathogen in some 
ARIs in children [79]. In our study, hRV was found in one third of samples 
and as single pathogen in approximately 10% of the cases. 
In the GENDRES cohort, infection by both RSV and hRV was the most 
common viral co-infection detected, but in the UK cohort the most common 
viral co-infections were RSV + hBoV and IV + hBoV. These differences most 
likely reflect the fact that UK patients were recruited during the 2009 
pandemic influenza season, but they may also reflect local differences in 
epidemiology and recruitment (including a higher proportion of PICU cases in 
the UK cohort).  
Bocavirus is a recently discovered virus that may cause ARIs, particularly in 
children, with the highest frequency found in hospitalized infants. Our results 
indicate that hBoV is commonly detected in respiratory samples of young 
children with LT-ARI, in agreement with previous reports [62,102]. In our 
study, hBoV was the third most frequently identified virus in the GENDRES 
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cohort, after RSV and hRV, and the fourth in the UK cohort. Our detection 
rates in both the GENDRES and UK cohorts (23.5% and 19.6%, 
respectively) are higher than those in other published series, which have 
reported variable prevalence ranges of 1.5–19%. Methodological factors may 
explain these differences: our cohorts included only hospitalized children, 
whereas other studies included inpatients and outpatients [62,103]. hBoV 
was rarely found as a single infecting agent: in most cases (87.5%) it was 
found together with other respiratory viruses, as previously observed 
[60,102,104]. RSV, hRV, AdV and hMPV viruses were the most frequently 
observed co-pathogens, as observed by other authors [105-107].  
In young children, hMPV is an important cause of bronchiolitis, accounting for 
5 – 15% of all cases [10,59,108]. In our study we found 27 (13.2%) hMPV-
positive samples in the GENDRES cohort. Of these, 66.7% of hMPV were 
detected as a co-infection with another respiratory virus, and 33.3% were 
found as a mono-infection. In the UK cohort four (4.1%) samples were 
hMPV-positive, including two with co-infection. Co-infection with hMPV has 
been proposed to increase disease severity in some studies [8,109,110], but 
not in others [111]. Dual infection with RSV is reportedly common, reflecting 
the overlapping seasonal distributions. One study reported that 70% of 
children with severe RSV bronchiolitis were co-infected with hMPV, 
suggesting that the disease caused by RSV may be augmented by a 
concurrent hMPV infection [110]. However, population-based and case 
control studies of hospitalized children have found that hMPV and RSV co-
infections are uncommon [108,109]. In our study, the low proportion of mono-
infected patients suggests that hMPV rarely produces clinically significant 
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infection by itself, but co-infection of hMPV with RSV was also uncommon 
(only two cases).  
Bezerra et al. [112] have observed that AdV is frequently detected as part of 
a co-infection, in contrast with the findings of Huang et al. [113]. AdV was 
reported to be responsible for 5 - 10% of ARI in children [11]. Our detection 
rate ranged between 9.3% (UK cohort) and 19.1% (GENDRES cohort) with a 
median age of 21.8 months.  
Our study detected a broad range of common respiratory pathogens but it 
was not exhaustive, and indeed it may have missed as yet undescribed 
respiratory pathogens. The study considered only children admitted with LT-
ARI, and did not include milder or asymptomatic infections. Several studies 
have shown that viruses can be found in children with no ARIs [93,114], and 
further research is needed to understand the respiratory viral carriage and 
infection. Although quantification of the virus load by PCR is possible, 
respiratory samples are heterogeneous, and different extractions of the same 
patient can lead to diverse results depending on chance variation in the 
amount of virus present in the aliquots extracted. Whilst the robustness of 
our findings is supported by the broad similarity between the two 
independent cohorts analyzed in the present study, its applicability to other 
populations is likely to be influenced by local epidemiological and host 
genetic factors. 
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5.2 Severity of the illness 
Our study revealed that even though multiple viral detection is frequent in 
hospitalized children with LT-ARI, this association is not related to either 
disease severity or to any other clinical features studied. PICU admission, 
disease severity according to different scales, need for respiratory support, 
and length of hospital stay followed a similar pattern in viral mono- versus co-
infected children. Contrariwise, bacterial superinfection increased the 
severity of the disease course, while pneumococcal vaccination played a 
protective role. 
The detection of multiple coincident viruses in clinical settings is becoming 
more common since the introduction of molecular based multiplex tests, but 
the clinical significance of these findings remains unclear and seems to have 
no impact in disease severity [115]. Both an increase in disease severity in 
relation to dual infections [93,97,116,117] and the absence of this association 
[7,74,94-96,99,105,111,118,119] have been reported. Richard et al. [116] 
found that co-infected children were almost three times more likely to be 
admitted to the PICU than those with single viral infections. Compared to our 
study Richard et al. developed a retrospective and monocentric study in 
which they only considered dual infections, infants and bronchiolitis.  
There is contradictory evidence linking disease severity with specific 
respiratory viruses. A shorter hospital stay has been reported in children with 
rhinovirus bronchiolitis than with RSV [120]. Rhinovirus and RSV co-infection 
is reported to increase the risk of severe disease [116] or the bronchiolitis 
relapse [121,122]. Other studies did not find significant differences in severity 
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between co-infection and single infection [96,118,123,124]. In our study we 
did not find increased severity of illness in children with RSV-rhinovirus dual 
infection. In our series, only RSV as mono-infection increased oxygen 
requirements, and rhinovirus as a co-infecting pathogen increased the Wood-
Downes score in the Spanish cohort, but these isolated findings arising from 
the multivariate analysis could not be replicated in the UK cohort. 
Several studies have reported increased severity with bocavirus (hBoV) co-
infections [9,105-107]; this was not the case in our series (also in agreement 
with Pen et al. [95]). hBoV was commonly detected in our patients, with no 
impact in the severity of the illness. As hBoV was detected in alongside other 
respiratory viruses with an established pathogenic potential, it is possible that 
hBoV detection reflects asymptomatic persistence or prolonged viral 
shedding [60]. 
Bacterial superinfection was the only factor consistently linked to greater 
severity. Studies of the pandemic influenza indicate that respiratory viruses 
predispose to bacterial complication and interaction between viruses and 
bacteria in respiratory infections has been extensively reported in the 
literature [78], but the underlying mechanisms between viral and bacterial 
synergism are complex and remain unclear [125]. Common respiratory viral 
infections, such as influenza or respiratory syncytial virus have been linked to 
seasonal increases in Streptococcus pneumoniae disease [126]. The 
relationship between bacterial and viral infection is clouded by the low 
sensitivity of bacterial detection in sterile-site samples by traditional culture 
methods, and the reliance on non-specific clinical data for the for diagnosis of 
bacterial co-infection, including inflammatory markers, radiological findings 
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and / or appropriate cultures, resulting in 30% of the cases in the GENDRES 
cohort and 55% in the UK cohort. Suspected or confirmed bacterial infection 
increased most measures of severity in both cohorts (PICU admission, 
respiratory support requirement, GENVIP score, hospital stay length and 
respiratory distress). 
Interestingly, pneumococcal vaccination was revealed as an independent 
protective factor of disease severity in our patients. Pneumococcal vaccine 
reduced the severity of viral LT-ARIs through a reduction in oxygen 
requirement, invasive and non-invasive ventilation, admission to PICU, 
respiratory distress, and GENVIP score. A reduced incidence of viral alveolar 
pneumonia has been previously reported after pneumococcal vaccination 
[126,127], although there was no demonstrable reduction in the number of 
confirmed pneumococcal infections. This is likely to reflect the limited 
sensitivity of culture-proven pneumococcal disease in pneumonia. 
One of the limitations of the present study is that our samples were not 
tested for viral load by quantitative PCR and the viral load of certain viruses –
like RSV- has been associated with the co-infection status and the severity 
[128]. Also, the study did not consider milder or asymptomatic children. In 
addition, bacterial super-infection rate in our series might be overestimated 
as diagnosis was accepted as true even without microbiological confirmation, 
just based on referring physicians’ criteria.  
Several studies had shown that viruses can be found in children with no 
respiratory infections [93,129], and further research is needed to understand 
the natural history of respiratory viral carriage and infection. However, our 
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findings were consistent in both independent cohorts very different between 
them, so this makes the outcomes more robust.  
5.3 Seasonal and geographical area 
distribution 
Similarly to other studies [99,130], our findings show a higher prevalence of 
hMPV infections in the late winter months and spring. It is usually detected 
from January to March in the northern hemisphere and peak of the hMPV 
seasonal cases is observed between March and April following the RSV and 
influenza infection seasons although it was also reported that the hMPV 
infection season overlaps with that of the RSV infection season[58]. García-
García [99] found a similar seasonal pattern of hMPV and RSV between the 
years 2000 - 2006, therefore this seasonal distribution seems unlikely to 
change from one year to another. As in our study, in an observational study 
developed by Gil-Prieto in Spain during the years 1997 - 2011, an important 
seasonality was observed in hospitalizations due to RSV, with 76% of the 
patients occurring between November and March. hBoV was found in a 
similar monthly distribution than in Calvo et al. [131] and VonLinstow et al 
[132], although the latter was a study in non-hospitalized Danish infants 
under 1 year old.  
Parainfluenzavirus is a common cause of respiratory illness and their 
seasonal epidemiology depends on the type; hPIV 1-2 has been reported to 
occur biennially usually during fall and early winter, hPIV 3 is endemic 
throughout the year but with peaks in April-May and hPIV 4 more irregularly 
and seldom [133]. 
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5.4 Bacteremia 
One out of every ten previously healthy children hospitalized due to RSV had 
bacteremia. These patients experienced a more severe disease and half of 
them had received empirical antibiotic therapy.  
The prevalence of bacteremia in children with RSV infection reported in the 
literature is low, ranging between 0.6 and 1.1% [65-67,134-136]. Our study 
found rates of concurrent bacteremia ten times higher (10.6%). In the studies 
cited, only conventional cultures were performed, whereas molecular 
methods were applied in our series. RSV has been linked to seasonal 
increases in S. pneumoniae disease [126], as well as to other viruses such 
as influenza, but the underlying mechanisms between viral and bacterial 
synergism are complex and remain unclear. Immunization programs with 
conjugate vaccines against invasive H. influenzae serotype b and 
Streptococcus pneumoniae have changed the frequency of bacteremia in 
febrile infants [126,134]. In our series, only 14.3% of the PCR positive 
patients had been vaccinated against pneumococcal disease, as compared 
to PCR negative ones, with 52.5% having received the vaccine.  
The diagnosis of bacterial superinfection is most often made on clinical 
grounds, and not always confirmed microbiologically. Antibiotics should not 
be administered to RSV-infected children unless complications such as 
secondary bacterial illness occur [137,138]. In our series, blood cultures were 
not carried out systematically, but only when a bacterial superinfection was 
suspected by the referring physician. Blood culture is considered the gold 
standard for bacteria detection, but has a low sensitivity and some bacteria 
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are difficult to culture. Blood PCR –much more sensitive– was performed in 
all the recruited patients but the clinical relevance of its positive result is not 
clear. Detecting circulating DNA in the blood by PCR has some limitations 
and it is essential to extrapolate always the results obtained to the clinical 
grounds to see if both PCR results and the clinical phenotype are consistent 
[139]. The quantitative PCR and the cycle threshold value are inversely 
correlated with the bacteria load and could be an indicator to avoid false 
positive results. In our cohort the cycle threshold was <20, but as we only 
have seven positive samples we could not establish maximum cutoff levels.  
In our series, the physician suspected bacterial superinfection in half of the 
cases, a proportion similar to that in Thibeault et al.’s study [140]. Even 
though a blood culture was obtained for the majority of our patients (72.7%), 
only 3.8% (n = 1) yielded a positive result. Furthermore, we failed to find any 
correlation between PCR-confirmed bacteremia and clinical suspicion of 
bacterial superinfection (Cohen’s kappa coefficient = 0.15). Therefore, in 
agreement with other studies [136,141], we found that children with 
uncomplicated bacterial RSV infection are often overtreated with empirical 
antibiotics. 
Empirical antibiotic treatment is often prescribed in practice to children 
hospitalized due to a confirmed viral ARI based on fever presence or 
persistence. Between 23 and 31% of cases of bronchiolitis are associated 
with fever [142], and in our series the fever rate (37 and 50%) was in the 
range previously described of 45 to 65% for children hospitalized with RSV 
[143]. However, the risk of bacteremia is low in febrile children with 
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bronchiolitis [66,68,142], as corroborated in our series, where fever was not a 
predictor for bacteremia (P-value = 0.733). 
Randolph et al. [144] studied the risk of bacterial infection in children infected 
with RSV admitted to PICU, and using blood culture they found a rate of 
bacteremia of only 0.6%. In our study, the rate of bacteremia found by PCR 
in children who required PICU admission is higher (25.0%), probably due to 
the higher sensitivity of molecular techniques. Bacteremic patients had a 
more severe course according to PICU admission rates, respiratory support 
necessity, clinical scales and length of hospitalization. Bloomfield et al. [136] 
suggest that empirical antibiotics should be considered for any child admitted 
to PICU with a RSV infection and requiring ventilator. In or series only half 
the patients who were admitted to PICU and required ventilatory support had 
a bacteremia revealed by PCR, meaning that antibiotic prescription might be 
superfluous in up to 50% of the cases. 
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6 CONCLUSIONS 
1. The use of molecular techniques -namely multiplex nested PCR- in the 
diagnostic approach of children admitted to hospital with ARI significantly 
increases the detection yield of viruses in children.  
2. The multiplex nested PCR used in this study provides a sensitive and 
specific approach to diagnose the most common and important viruses 
involved in respiratory infections. 
3. RSV is the pathogen most frequently found in children hospitalized with 
acute respiratory infection, being present from one third to one half of the 
cases. 
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4. Co-infection with multiple viruses is very frequent in children hospitalizaed 
with acute respiratory infection, being found in 30 to 45% of the cases. 
5. Co-infection with multiple viruses increases with age up to 48 months of 
age, being most frequent in the 12-24 months age group.  
6. The virus co-infection pattern most frequently observed is RSV-
Rhinovirus and RSV-bocavirus/bocavirus-influenza. 
7. The pattern of viral co-infection did not correlate with any marker of 
disease severity. 
8. The presence of more than one virus in children hospitalized with acute 
respiratory infection is very frequent although the clinical significance of 
this finding remains unclear.  
9. The presence of more than one virus in hospitalized children with ARI is 
very frequent but it does not seem to have a major clinical impact in terms 
of severity. 
10. Bacterial superinfection was associated with increased severity according 
to PICU admission rate, clinical score, need of respiratory support and 
length of hospital stay.  
11. Pneumococcal vaccination was found to be a protective factor in terms of 
severity according to degree of respiratory distress, PICU admission rate, 
clinical score, need of respiratory support and oxygen necessity. 
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12. In previously healthy children with a positive RSV respiratory illness, a 
bacteria is found in one of each ten cases. 
13. Concurrent bacteremia is not frequent in infants and children hospitalized 
with RSV respiratory infection, even in the presence of fever and despite 
the use of molecular techniques for the diagnosis, and thus, antibiotics 
are usually overused in the setting of RSV infection.  
14. RSV infected children with bacteremia had more severe disease than 
those without bacteremia, according to PICU admission rate, need of 
respiratory support, Wood-Downes score, GENVIP scale and length of 
hospitalization. 
15. Bacteremia may actually occur in children with RSV infection and we 
have not found a reliable predictive clinical pattern, although our sample 
size is limited to draw definite conclusions in this regard. 
16. Further studies assessing co-infection in children with mild illness and 
healthy control groups are needed in order to better understand its clinical 
relevance.  
17. Future studies are needed to investigate whether particular viruses, or 
combinations of virus, influence the risk of bacterial co-infection. 
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7 FUTURE 
CHALLENGES 
The findings of this thesis could contribute to the ongoing discussion of the 
importance of diagnostic ability to reliably detect multiple concurrent 
pathogens in a single patient. The multiplex PCR in nasopharyngeal samples 
and in blood, searching in this one for bacterial infection, provides useful 
information on the etiology of the respiratory infections. The use of this 
method also provides important information to better understand the 
epidemiology of respiratory infections as well as for infection control. One 
advantage of the use of the multiplex PCR method is that it may reduce 
antibiotic prescription rates at medical attendance in children with ARI, in an 
inpatient or even in an outpatient setting.  
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It is important to keep in mind that genome detection methods (as PCR) 
detect only the specific gene sequence of the microbial agent that the 
primers are designed to bind to. If the agent has mutated in such a way that it 
affects the gene sequence targeted, no amplification will occur and the 
analysis will be a false negative. However, in order to avoid this, the primers 
of all agents are targeted at a conserved region of the genome. It can also 
occur that a virus or a bacterium is not detected because it is not included in 
the PCR panel but may be present in the patient sample. This may happen 
especially in new or not discovered virus. 
Consequently with the still open questions of this study, new lines of 
research have been developed: 
For further studies, it would be interesting to undertake a large study 
including control samples. A large prospective study, investigating the 
prevalence of pathogens in samples from children with no respiratory 
symptoms would be very useful, and may put some of our results into context 
in terms of the likelihood of the particular pathogens being causative in each 
case. 
Another area of interest would be to perform the same panel of 19 viruses to 
mild symptomatic children, and compare the PCR results, in the same 
epidemic period, with those who are admitted to hospital.  
We also have developed genetic studies in which we aim to identify the 
genes that determine susceptibility and severity in respiratory infections of 
childhood. We will use RSV bronchiolitis as the prototypic model to develop 
an integrated staged approach to identify the genetic basis of both 
susceptibility to infection and severity of disease in those affected, as it is the 
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most prevalent ARI in children, and then apply this model to the other major 
respiratory infections of childhood. In this research line, extreme phenotypes 
of RSV infection are going to be studied. With this propose, we are going to 
carry out whole exome sequencing (WES) that permits analysis of the DNA 
sequence for all protein-coding areas of the human genome. By comparison 
of patients’ DNA sequence to the reference genome, we can identify the 
DNA changes (variants) present in that individual that may have functional 
consequences. 
Another research line is to study the transcriptome of RSV. Next generation 
sequencing (NGS) is capable of sequencing, in parallel and massively, 
millions of cDNA fragments in a single sequencing process rapidly and 
relatively inexpensively. Massive sequencing techniques of total RNA (RNA-
Seq) offer the opportunity to obtain global information of transcriptomic status 
of a specific tissue, or even a single cell, not only providing information about 
gene expression levels but also allowing the identification of alternative 
splicing events, unknown transcripts, processes of gene fusion or 
identification of mutations simultaneously.  
Finally, we would like to study in future studies drugs that could modify the 
respiratory illness and vaccines to prevent them. In this regard, we are 
involved in clinical trials with new RSV drugs and vaccines. In the other hand, 
we are investigating the potential protective role of vitamin D in respiratory 
infections. It is known that vitamin D is known to play a major role in calcium 
metabolism and bone health, stimulating intestinal absorption of calcium and 
phosphorus, and regulating serum calcium levels in order to maintain an 
adequate mineralization of the bones. But in recent years, aside from this 
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main role, observational studies suggest that low levels of vitamin D may 
contribute to an increased risk of many different diseases, including ARI. As 
the relation between levels of vitamin D and severity of the respiratory 
episode is not yet clear, our aim is to prospectively assess the influence of 
vitamin D levels in infants admitted to hospital due to an ARI and its possible 
relationship with the severity of involvement 
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Appendix Figure 1. GENDRES informed consent used for this study. 
Appendix Figure 2. GENDRES case reported form used for the study. 
Appendix Table 1. Demographic characteristics, family and patient medical 
history, clinical course and principal virus in children with ARI and disease 
severity, considering respiratory support and oxygen requirement the 
characteristics that described the severity of the illness of the main cohort. A 
binary logistic model was used. Data are presented as OR (95% confidence 
interval) and the level of statistical significance was set at 0.05. Two multiple 
test correction were considered: Bonferroni correction and FDR 
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Appendix Table 2. Variables analyzed in children with ARI and disease 
severity, considering the clinical scales the characteristics that described the 
severity of the illness of the main cohort. A linear model for continuous 
variables was used and the level of statistical significance was set at 0.05. 
Two multiple test correction were considered: Bonferroni correction and FDR. 
Appendix Table 3. Demographic characteristics, family and patient medical 
history, clinical course and main virus in children with ARI and disease 
severity in GENDRES cohort. A binary logistic model was used for the binary 
variable (PICU admission) and a negative binomial regression model for 
counted data (hospital stay length). Data are presented as OR (confidence 
interval 95%) and the level of statistical significance was set at 0.05. Two 
multiple test correction were considered: Bonferroni correction and FDR. 
Appendix Table 4. Children’s with ARI characteristics and moderate and 
severe respiratory distress. A logistic multinomial model was used and mild 
status was fixed as category of reference. Level of statistical significance was 
set at 0.05. 
Appendix Table 5. Comparison of virus and disease severity of the main 
cohort considering the virus as single pathogen or as co-infection in the 
sample. Different statistical models were considered to study the bivariate 
association between the variables depending on the dependent variable. A 
binary logistic model was used for the binary variables oxygen needed and 
respiratory support needed, and a negative binomial regression model for 
counted data (hospital stay length). Data are presented as OR (confidence 
interval 95%) and the level of statistical significance was set at 0.05 
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Appendix Table 6. Comparison of virus and disease severity of the 
replication cohort (UK cohort) considering the virus as single pathogen or as 
co-infection in the sample. Different statistical models were considered to 
study the bivariate association between the variables depending on the 
dependent variable. A binary logistic model was used for the binary variables 
oxygen needed and respiratory support needed, and a negative binomial 
regression model for counted data (hospital stay length). Data are presented 
as OR (confidence interval 95%) and the level of statistical significance was 
set at 0.05. 
Appendix Table 7. Demographic characteristics, clinical course and main 
virus in children with ARI and disease severity, considering respiratory 
support and oxygen requirement the characteristics that described the 
severity of the illness of the UK-cohort are presented. A binary logistic model 
was used. Data are presented as OR (95% confidence interval) and the level 
of statistical significance was set at 0.05. 
Appendix Table 8. Variables analyzed in the UK-cohort children and 
disease severity according to hospital stay length and PICU admission are 
shown. A binary logistic model was used for the binary variable (PICU 
admission) and a negative binomial regression model for counted data 
(hospital stay length). Data are presented as OR (confidence interval 95%) 
and the level of statistical significance was set at 0.05. 
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  .   
Gen-D-Res. Hoja de información y consentimiento informado                                                                                                     Pág. 4 de 5 
 
 
Consentimiento informado Versión 2.0 del 31OCT2014                                                          Protocolo Gen-D-Res 
Proyecto-Gen-D-Res: Evaluación de la influencia del componente genético y de  
los niveles de vitamina D en la susceptibilidad individual y pronóstico de la  
infección por virus influenza H1N1 y otros virus respiratorios. 
 
Consentimiento Informado 
 
Si ha comprendido la información que se le ha proporcionado, ha resuelto cualquier duda que pudiese tener y 
decide que su hijo/a colabore con este estudio de investigación en los términos indicados en la hoja de información 
que se le entrega junto con este consentimiento, por favor, lea y firme a continuación. 
Al firmar este documento, acepta que su hijo/a participe en este estudio de investigación y otorga permiso para 
que se utilice la información de su hijo/a de acuerdo a la legislación de protección de datos vigente, sin renunciar a 
ninguno de los derechos legales que le corresponde a su hijo.  
  
 
1. Confirmo que he leído y entendido la hoja de información para padres/tutor legal (versión 2.0, del 
31 de octubre de 2014) para el estudio Gen-D-Res y que se me ha dado una copia del presente 
documento para guardar. He tenido la oportunidad de preguntar mis dudas y estas han sido 
respondidas satisfactoriamente. 
 
F 
2.  Entiendo que la participación de mi hijo/a es voluntaria y que soy libre de retirar mi 
consentimiento en cualquier momento sin necesidad de dar ninguna explicación y sin que la 
atención de mi hijo/a o sus derechos se vean afectados en modo alguno. 
 
F 
3.  Comprendo que los datos personales y clínicos recogidos con motivo del estudio en relación con 
mi hijo/a serán exclusivamente manejados por personal responsable del estudio y preparado para 
hacerlo, garantizando la protección de estos datos de acuerdo a la ley vigente (Ley 15/1999). Doy 
mi permiso para que estas personas, y en las condiciones señaladas, puedan acceder al historial 
clínico de mi hijo/a. 
 
F 
4 
 
 
5. 
  
Acepto que las muestras obtenidas de mi hijo/a de sangre, saliva y moco se utilicen en este 
proyecto de acuerdo a lo descrito en la hoja de información al paciente 
 
Acepto que las muestras obtenidas de mi hijo/a en este estudio puedan ser utilizadas en otros 
estudios futuros siempre que hayan sido aprobados por un comité ético y se garanticen al menos 
las mismas condiciones que en el presente estudio.  
 
F 
 
F 
6.   Acepto que mi hijo/a participe en este proyecto de investigación. F 
 
______________________________________________________                                   
Nombre del sujeto participante                                         
 
______________________________________________             _________________              _________________ 
Nombre del padre/tutor                                       Firma                          Fecha 
 
______________________________________________             _________________              _________________ 
Nombre de la madre/tutora                                      Firma                          Fecha 
 
Si solo un progenitor firma este documento, por favor, complete la siguiente casilla: 
   F Confirmo con la presente que el otro progenitor no se opone a la participación de nuestro hijo/a en el estudio.  
   F El firmante es el único tutor legal. 
 
______________________________________________             _________________              _________________ 
Nombre del facultativo                                      Firma                          Fecha 
 
COPIA PARA LOS PADRES/TUTOR 
Appendix Figure 1 
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Nº centro
Nº historia
Fecha de nacimiento
Provincia nacimiento paciente
Provincia  nacimiento padre
Atención médica recibida
Algún episodio previo
Otra enferm. pulmonar crónica
Prematuro
Otros
Recibe suplemento de vit D
Otros ingresos de interés
Otros tratamientos de interés
Asma
Diabetes
Obesidad
Motivo de atención/ingreso
Afectación respiratoria
Score Wood-Downes
Necesitó oxígeno
Necesitó soporte respiratorio
Diagnóstico
Otros diagnósticos OMA Otros. Especificar
VRS Influenza Otros. Especificar:
Sobreinfección bacteriana
Vacunado Especificar: 7 10 13
Tratamiento antivírico
Tratamiento antibiótico
Ingreso hospitalario
Cita CAP Atención en urgencias
Otro agente. Especificar
Si No
Si No Especificar
Si No
Si No
Especificar
Si No Especificar
Datos evolutivos
Si No
Si No
No identificado No pruebas microbiologicas
(0-10)
Especificar
Atención Fecha de la atención / ingresoIngreso
Recibió madre durante embarazo suplem de vit. D
Problemas respiratorios
Asma
Si No
No
Mujer
Si No Especificar dosis/duración
Cuestionario de datos 
GENDRES
Datos de filiación general y genética
Provincia nacimiento madre
Antecedentes familiares
Pegatina paciente
Especificar
(bronquiolitis, hiperreact. bronquial, dificul. resp. baja)
Datos clínicos
Datos diagnósticos
Ventilación mecánica
Si No
Si No
Si
Especificar
Antecedentes personales
Evolución Sin secuelas Con secuelas. Especificar
Especificar:
Agente etiológico
Duración del ingreso (días)
Influenza H1N1
Si No
Otros datos relevantes o de interés
Si No Especificar
Éxitus
Alta
Especificar
Gitana
Código paciente webNº paciente
Score Si No
HombreSexo
Edad (años/meses)
Etnia Europeo occidental
Africano-Subsahariano Norteafricano
Americano Sur
Antineumocócica
No Si
Si No
Bronquiolitis Neumonía
No Ventilación no invasiva
Ninguna Leve Moderada Grave
Si No
Si No Especificar
Broncoespasmo Infección vías altas
Reagudización asma HRB
Gripe estacional
Appendix Figure 2 
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Respiratory distress 
Variable 
Moderate Severe 
Coefficient (95% CI) P-value Coefficient (95% CI) P-value 
Demographic characteristics 
Sex (female proportion) 1.060 (0.557, 2.018) 0.860 0.693 (0.248, 1.933) 0.483 
Family history 
Asthma 2.274 (0.467, 3.473) 0.636 1.262 (0.289, 5.517 0.757 
Respiratory conditions 1.000 (0.419, 2.385) 1.000 1.462 (0.434, 4.923) 0.540 
Patient medical history 
Premature birth 0.666 (0.201, 2.205) 0.666 2.063 (0.500, 8.514) 0.317 
Pulmonary conditions 0.237 (0.042, 1.334) 0.102 0.598 (0.063, 5.642) 0.598 
Asthma 1.274 (0.467, 3.473) 0.636 1.262 (0.289, 5.517) 0.757 
Pneumococcal vaccine 1.212 (0.644, 2.280) 0.552 2.917 (1.078, 7.889) 0.035 
Clinical data 
Bacterial superinfection 0.877 (0.420, 1.831) 0.727 4.356 (1.564, 12.128) 0.005 
Co-infection 0.915 (0.477, 1.756) 0.790 1.615 (0.570, 4.578) 0.367 
Virus 
RSV 0.858 (0.459, 1.604) 0.632 1.406 (0.532, 3.718) 0.492 
Rhinovirus 1.251 (0.634, 2.469) 0.519 1.765 (0.657, 4.739) 0.260 
Bocavirus 1.036 (0.498, 2.152) 0.925 0.643 (0.188, 2.199) 0.481 
Adenovirus 1.404 (0.606, 3.248) 0.429 1.111 (0.307, 4.024) 0.873 
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